USP50 in the DNA damage response and the role of BRACA1 at stalled replication forks by Lawrence, Kirsty Josephine
ii | P a g e  
 
 
 
USP50 IN THE DNA DAMAGE 
RESPONSE 
 
and 
 
THE ROLE OF BRCA1 AT STALLED 
REPLICATION FORKS 
 
By 
 
Kirsty Josephine Lawrence, BSc 
 
 
 
 
This project is submitted in partial fulfilment of the requirements for 
the award of MASTER OF RESEARCH BIOMEDICAL 
RESEARCH to the University of Birmingham 
 
 
 
School of Cancer Studies 
College of Medical and Dental Sciences 
University of Birmingham 
August 2012 
 
 
 
 
 
 
 
 
 
University of Birmingham Research Archive 
 
e-theses repository 
 
 
This unpublished thesis/dissertation is copyright of the author and/or third parties. 
The intellectual property rights of the author or third parties in respect of this work 
are as defined by The Copyright Designs and Patents Act 1988 or as modified by 
any successor legislation.   
 
Any use made of information contained in this thesis/dissertation must be in 
accordance with that legislation and must be properly acknowledged.  Further 
distribution or reproduction in any format is prohibited without the permission of 
the copyright holder.  
 
 
 
iii | P a g e  
 
USP50 IN THE DNA 
DAMAGE RESPONSE 
 
AND 
 
THE ROLE OF BRCA1 AT 
STALLED REPLICATION 
FORKS 
By 
Kirsty Josephine Lawrence, BSc 
  
iv | P a g e  
 
USP50 IN THE DNA DAMAGE RESPONSE 
The little-known deubiquitinating enzyme, USP50, has recently been observed to be 
important for G2/M cell cycle checkpoint activation and ubiquitin conjugate clearance at 
DNA damage repair. This project investigates the possible orthologs, predicted protein 
structure, protein domain active sites, conserved protein regions and cellular localisation of 
USP50. Also, this details the cloning strategy of creating wild-type and mutant USP50 
inducible expression stable cell lines. Methodology utilised included; bioinformatics tools, 
protein structure modelling, immunofluorescene staining and cell culture. 
USP50 is a close homologue of USP8 but has a missing catalytic residue in the active site 
required for ubiquitin binding. Immunofluorescent data suggests USP50 is functional as 
overexpression leads to cellular defects and DNA damage. Due to such damage, inducible 
expression stable cell lines of wild-type and mutant USP50 are required to study USP50 
function further.  
Evidence within the literature combined with our results suggest USP50 is active, despite 
the missing residue from its UCH active site. USP50 appears to be important for ubiquitin 
conjugate regulation at double-strand breaks.  
 
 
THE ROLE OF BRCA1 AT STALLED REPLICATION FORKS 
BRCA1 is a common inherited mutation in families with early onset breast and ovarian 
cancer. Cancers with homozygous mutations in BRCA1 are more resistant to chemotherapy 
due to abnormal DNA repair. Gemcitabine is a DNA replication inhibitor used to treat 
breast and ovarian cancer. How cancer mutations change the response of cells is poorly 
understood. Here, we investigate how BRCA1 mutations effect response to Gemcitabine 
using the cell line, HCC1937. BRCA1-proficient and –deficient cells were used to 
investigate the replication fork stalling, fork restart, 53BP1 and ɣH2AX foci, phospho-RPA 
levels, cell cycle accumulation and clonogenic survival after Gemcitabine treatment. 
Techniques utilised included DNA fibre analysis, immunofluorescent staining, FACS, 
Western blot and clonogenic survival assays.  
BRCA1-deficient cells display increased fork stalling and earlier induction of phospho-
RPA, 53BP1 and ɣH2AX. BRCA1 status effects the accumulation of cells in S phase after 
Gemcitabine treatment. BRCA1-deficient cells show decreased survival to <10µM 
Gemcitabine treatment.  
We report that BRCA1 protects slowed and stalled forks, and prevents forks collapsing into 
double-strand breaks. BRCA1 status affects the sensitivity of cells to Gemcitabine 
treatment.  
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USP50 IN THE DNA DAMAGE RESPONSE 
ABSTRACT 
The little-known deubiquitinating enzyme, USP50, has recently been observed to be 
important for G2/M cell cycle checkpoint activation and ubiquitin conjugate clearance at 
DNA damage repair. This project investigates the possible orthologs, predicted protein 
structure, protein domain active sites, conserved protein regions and cellular localisation of 
USP50. Also, this details the cloning strategy of creating wild-type and mutant USP50 
inducible expression stable cell lines. Methodology utilised included; bioinformatics tools, 
protein structure modelling, immunofluorescene staining and cell culture. 
USP50 is a close homologue of USP8 but has a missing catalytic residue in the active site 
required for ubiquitin binding. Immunofluorescent data suggests USP50 is functional as 
overexpression leads to cellular defects and DNA damage. Due to such damage, inducible 
expression stable cell lines of wild-type and mutant USP50 are required to study USP50 
function further.  
Evidence within the literature combined with our results suggest USP50 is active, despite 
the missing residue from its UCH active site. USP50 appears to be important for ubiquitin 
conjugate regulation at double-strand breaks.  
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INTRODUCTION 
Ubiquitin, Ubiquitination and Deubiquitination 
Ubiquitin is a highly conserved 76 amino acid protein which has 7 lysine residues (K6, 11, 
27, 29, 33, 48 and 63) (Haas and Siepmann, 1997). It plays a role in the post-translational 
modification of proteins. Ubiquitin modifications are involved in signalling for the 
degradation and the re-localisation of proteins, and it is because ubiquitin is a marker for 
timely action, that it is important in cell regulatory processes. The addition of ubiquitin 
modifications has been shown to have multiple functions in the cell; in particular it is 
involved in degradation of proteins by the proteasome (Eytan et al., 1989) and localisation 
or trafficking of proteins within the cell (Hicke and Dunn, 2003). The efficient degradation 
of protein is heavily involved in cell cycle progression, endocytosis and various regulatory 
pathways of transcription (Chen and Sun, 2009) and antigen response signal transduction 
(Ben-Neriah, 2002). Therefore ubiquitin is involved in correct immune response (Ben-
Neriah, 2002), programmed cell death and the regulation of developmental processes (Chen 
and Sun, 2009), and consequently aberrant ubiquitin modification is associated with 
diseases such as cancer (Beer-Romero et al., 1997). 
Ubiquitin chains can form using the seven conserved lysines in ubiquitin. Two types of 
ubiquitin chain are linked by Lys48 (K48, PDB:3NS8) or Lys63 (K63, PDB:2JF5) and 
have specific structures. The type of chain can mark the protein for various fates. For 
example, K48 chains can promote degradation of the protein by the proteasome (Verma et 
al., 2004), whereas K63 chains can mark proteins for localization to the lysosome (Varadan 
et al., 2004; Yang et al., 2010). 
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The ligation of ubiquitin to a protein requires three types of enzymes; E1, E2 and E3. The 
E1 ubiquitin-activating enzyme binds and activates ubiquitin at a C-terminus glycine in an 
ATP-dependent manner. The ubiquitin is moved to a cysteine residue on the E1 and 
subsequently transferred to the cysteine residue in the active site of an E2 ubiquitin-
conjugating enzyme. An E3 ubiquitin-protein ligase then transfers the ubiquitin onto a 
lysine residue of the protein substrate. E1’s can bind to several E2 enzymes, and E2 can 
bind to many E3 enzymes, and it is the E3 that confers the specificity for a protein substrate 
(Pickart and Eddins, 2004).  
The regulation of ubiquitin modifications is aided by deubiquitinating-enzymes (DUBs) 
which remove ubiquitin from proteins so they are no longer modified (Lam et al., 1997). 
This maintains the function of various proteins and maintains a constant pool of free 
ubiquitin in the cell. DUBs are categorised into two main classes; metalloproteases and 
cysteine proteases. 
Metalloproteases contain JAMM domains that bind to zinc. Cysteine proteases have four 
superfamilies; ubiquitin-specific processing protease (USP/UBP), ubiquitin C-terminal 
hydrolyase (UCH), Ovarian tumour (OTU) and Machado-Josephin domain (MJD) 
superfamilies (Amerik and Hochstrasser, 2004). The catalytic domains of the cysteine 
protease superfamilies are slightly different, but all have a cysteine and a histidine residue 
as part of the active site. Other residues that are important include a glycine residue and an 
aspartate residue although they are not essential (Nijman et al., 2005). 
Evolution of E1, E2, E3 ubiquitin enzymes and DUBs 
Ubiquitin modifications of target proteins are important for developmental processes in 
Caenorhabditis elegans and four of the 20 nematode E2 enzymes are essential for 
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embryogenesis. When gene expression is altered, these essential E2 enzymes mainly cause 
tail malformations (Jones et al., 2002). Outside of developmental biology, genome research 
has suggested that E3-ligases and DUBs increased in number through eukaryote evolution. 
Mammals possess higher numbers of E3-ligases and DUBs than D. melanogaster, C, 
elegans, S. pombe and S. cerevisiae. When comparing the ubiquitin-related and unrelated 
domains in E1, E2, E3 and DUB enzymes, there was a 2.5 fold increase of non-ubiquitin 
associated domains in the human and mouse E3 enzymes and DUBs. This suggests that 
mammalian E3’s and DUBs coevolved and also developed regulatory functions, other than 
ubiquitin binding (Semple et al., 2003). This may have aided the evolution of the substrate 
specificity and allowed a greater degree of regulation in mammals and not in lower 
eukaryote species.  
Ubiquitin in the double-strand break response 
Ubiquitin is heavily associated with DNA damage repair (DDR) pathways and plays a 
major role in the sequential accumulation of proteins at sites of damage. After a double 
strand DNA break (DSB) is detected, ATM phosphorylates H2AX histones (Burma et al., 
2001) which is quickly bound by MDC1. The E3 ligase, RNF8 (Stucki et al., 2005), binds 
to MDC1 and initiates the ligation of ubiquitin onto the surrounding histones, signalling for 
the early response DNA damage proteins to accumulate (Huen et al., 2007). H2A and 
H2AX ubiquitination by RNF8 (Lok et al., 2012) allows RNF168 to accumulate at sites of 
damage which has E3 ligase activity that amplifies the ubiquitination of the surrounding 
H2A histones (Doil et al., 2009; Stewart et al., 2009). It has been shown that the E2 
enzyme, Ubc13 (VanDemark et al., 2001), specifically forms K63-linked chains on the 
histones (Plans et al., 2006). 
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MDC1 and RNF8 are associated in complex with the E3 ligase HERC2 (Bekker-Jensen et 
al., 2010). HERC2 has been shown to promote the interaction between RNF8 and Ubc13 
(Plans et al., 2006; Wang and Elledge, 2007), which allows the specific formation of K63 
chains at sites of damage (Campbell et al., 2012), which are required for BRCA1 
accumulation (Wang and Elledge, 2007). 
BRCA1, an E3 ligase, has many roles in the DDR and associates with ubiquitinated 
histones via a protein complex with RAP80, Abraxas (Wang and Elledge, 2007), BRE, 
BRCC36 (Dong et al., 2003), Cdc98 (Liu et al., 2007) and NBA1 (Feng et al., 2009). The 
central protein of this complex is RAP80 (Kim et al., 2007) which has 3 Ubiquitin 
Interacting Motifs (UIMs), that confer specificity to K63-linked chains (Sato et al., 2009). 
Histone ubiquitination also promotes 53BP1 accumulation at sites of DDR (Acs et al., 
2011; Mallette and Richard, 2012) although this process is not fully understood. 
RNF168 deficiency in RIDDLE syndrome shows altered BRCA1 and 53BP1 accumulation, 
but not RAD51 recruitment (Stewart et al., 2009), which would suggest that RAD51 may 
be recruited independently of RNF168 (Mailand et al., 2007). Also, RIDDLE patients do 
not show altered replication stress, however RNF8 depletion causes replication fork 
collapse.  
This suggests that there may be two DDR pathways that occur after RNF8 ubiquitination; 
firstly, RNF168-dependent pathway that is associated with K63 chains leading to BRCA1 
and 53BP1 recruitment, and secondly, a VCP (Vasolin containing protein)-associated 
pathway that involves K48 chains and involves RAD51 recruitment (Acs et al., 2011; 
Ramadan, 2012). 
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The VCP-UFD1-NPL4 complex is recruited to DSBs by RNF8 (Meerang et al., 2011). 
RNF8 interacts with UbcH8, an E3 ligase, which can make K48 chains (Lok et al., 2012). 
The recruitment of VCP is independent of RNF168 and K63 chains and dependent on 
RNF8 and the formation of K48 chains (Meerang et al., 2011). It has been shown that there 
is an increase in the accumulation of K48-linked chains at DSBs when VCP is depleted. 
This suggests that VCP functions to specifically remove K48-linked ubiquitin and it is the 
interaction between RNF8 and VCP that regulates the turnover of K48-ubiquitin chains at 
the sites of DSB (Meerang et al., 2011). When looking at recruitment of proteins 
downstream of RNF8, it was shown that depletion of VCP partially effects BRCA1 and 
53BP1, but does not reduce the accumulation of Rad51 (Meerang et al., 2011).  
DUBs in the double-strand break response 
DUBs have also been shown to be active in the DDR, such as USP3 which, when 
overexpressed, stops RAP80 and 53BP1 recruitment by deubiquitination of H2A and 
H2AX histones (Nicassio et al., 2007). The DUB BRCC36 is seen to localise to sites of 
damage and promotes DDR signalling involved in arresting the cell cycle at the G2/M 
checkpoint (Dong et al., 2003). BRCC36 regulates the reversal of K63-Ubiquitin chains 
(Shao et al., 2009) which alters the recruitment of 53BP1. The 19S proteasome DUB, 
POH1, has been shown to stimulate the cleavage of polyubiquitin chains from H2A 
histones at sites of DDR and without POH1 the cells become sensitive to DNA damaging 
agents such as ionising radiation (IR) (Butler et al., 2012). POH1 localises to DNA damage 
foci where it deubiquitinates K63-linked ubiquitin chains on H2A histones (Cooper et al., 
2009). Processing of these chains regulates the accumulation of DNA repair proteins such 
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as BRCA1, which implicates POH1 in the regulation of homologous recombination (HR) 
following induction of DSBs. 
It has been shown that DUBs can be specific to a particular polyubiquitinated lysine chain. 
K63 chains create a different structure (Varadan et al., 2004) than K48 ubiquitin chains and 
USP8 and USP14 cleave only K48 chains (Avvakumov et al., 2006; Borodovsky et al., 
2001). Ubp2, a yeast DUB, acts conversely, cleaving only K63 chains (Kee et al., 2005). 
The specificity of a DUB can regulate the active function of the protein substrate, but in the 
case of USP8, which acts on NRDP1, it serves as an antagonist to a protein that catalyses 
its own degradation and regulation (Wu et al., 2004).  
Introducing USP50 
When DNA damage occurs the levels of polyubiquitin chains at sites of damage increases 
leading to the accumulation of DDR proteins for repair. These ubiquitin chains are cleaved 
within a number of hours following damage. In a screen of mammalian DUBs using an 
antibody specific for polyubiquitin chains, Ubiquitin-specific protease 50 (USP50) 
depletion was seen to decrease the levels of polyubiquitin chains that accumulated after 
DNA damage (Figure 1). This suggests USP50 may play a role in maintaining 
polyubiquitin chains for the effective repair of DNA. The process by which USP50 is 
potentially protective of ubiquitin chains is currently unknown. The depletion of USP50 
also increases ɣH2AX staining suggesting the occurrence of spontaneous damage (Stone 
and Morris, unpublished data).  
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This project focuses on this 
little-studied DUB, USP50. 
USP50 is found on 
chromosome 15, on the q 
arm at 21.1 and contains a 
UCH domain. The UCH 
domain is a conserved DUB 
region that contains a 
catalytic triad around the 
active site made up of three residues; a cysteine, a histidine and an aspartate residue 
(Johnston et al., 1999). The thiol group of the cysteine becomes deprotonated by the 
histidine, which itself is polarised by the aspartate residue. This allows the cysteine to form 
a nucleophilic bond, replacing the peptide bond between an ubiquitin and the protein 
substrate, with a bond between the ubiquitin and the DUB. This releases the protein 
substrate from ubiquitin. A water molecule then stabilises the ubiquitin, releasing it from 
the DUB (Johnston et al., 1999).  
Bioinformatic analysis of DUBs suggests that if one of the catalytic triad is missing then 
the protein becomes non-functional or inactive (Nijman et al., 2005). USP50 is lacking the 
aspartate residue of the catalytic triad (Ye et al., 2009) due to a truncation of the protein 
caused by a nonsense mutation. However, other USPs that lack the aspartate residue, 
namely USP30 (Nakamura and Hirose, 2008) and USP16 (Kinner and Kalling, 2003), still 
show some enzymatic activity. This could be due to neighbouring residues stabilising the 
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histidine residue as in Otubain-2 protein (Nanao et al., 2004). This is not the case with the 
truncated USP50. 
USP50 in the G2/M checkpoint response 
There is very little information about the functional aspects of USP50. One paper suggested 
that USP50 is involved in regulation of Wee1 stability through HSP90, which affects the 
CDC25B-dependent G2/M checkpoint of cell cycle (Aressy et al., 2010). Wee1, a cell cycle 
inhibitory kinase that plays a role in ensuring the correct activation of the G2/M checkpoint 
(van Vugt et al., 2004). USP50 was isolated using another siRNA screen of human DUBs 
that showed, after DNA damage, an increase in G2/M checkpoint bypass when CDC25B 
was overexpressed (Aressy et al., 2010). USP50 showed approximately a 1.5-fold increase 
in illegitimate entry of mitosis following DNA damage. USP50 was shown to be a binding 
partner of HSP90, a protein that controls the stability of associated proteins by functioning 
as a chaperone. USP50 depletion caused a loss of Wee1 that allows the increased 
illegitimate entry to mitosis. Proteasome inhibitors partially rescued the levels of Wee1 
(Aressy et al., 2010), suggesting that USP50 has a role in preventing Wee1 from being 
degraded by the proteasome. Therefore USP50 is involved in specifically stabilising Wee1. 
The paper looks at the localisation of USP50 in the cell as Wee1 is mainly found in the 
nucleus, and USP50 is predicted to be a cytoplasmic protein. After damaging cells with 
double strand DNA (dsDNA) damaging agents they reported that USP50 is relocated from 
the cytoplasm to the nucleus in response to etoposide and IR. Overall, the paper shows 
USP50 as a negative regulator of the G2/M checkpoint pathway (Aressy et al., 2010).  
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USP50 interactors 
As specificity of DUBs to protein substrates is important for appropriate regulation of the 
targeted protein, it is important to look at the proteins that may functionally interact with 
USP50 as substrate for deubiquitinating activity. The Harper Lab Comparative Proteomic 
Analysis Software Suite (CompPASS) uses an unbiased comparative approach to identify 
high-confidence candidate interacting proteins (HCIPs) from Immunoprecipitation-Mass-
Spectrometry/Mass-Spectrometry (IP-MS/MS) experiments. They use various statistics and 
scoring methods to identify possible functional interacting proteins. They performed IP-
MS/MS on a screen of 102 human DUBs (Sowa et al., 2009). The Total Spectral Count 
(TSC) of a DUB interacting proteins from the IP-MS/MS experiment is duplicated with 
several runs and the protein abundance values from these duplicates feed into the scoring 
methods, such as the WD (Weighted-Duplicate) scoring method. WD
N
 (WD number) score 
relates to the abundance of the protein and its interactor, factoring in the background level 
of interaction that leads to identifying false interactors and the frequency of the interactor 
being identified.  
The top ten USP50 interacting proteins are shown in the Table 1 with their WD
N
 scores and 
a description of their known function. 
Most notable of these interactors, is VCP, which is also known as p97 and Cdc48. VCP was 
originally discovered due to its high abundance in the cell and has been suggested to have a 
broad range of functions. VCP interacting proteins can be divided into two categories; 
adaptors, that aid VCP in recruiting many substrates, and substrate processing factors 
(Ramadan, 2012).  
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VCP binds to several DUBs such as VC1P135, Otu1, and Ataxin-3. The VCP-UFD1-NPL4 
complex, as previously mentioned, has a key role in the regulation of ubiquitin during the 
DDR (Meerang et al., 2011). VCP accumulation requires K48 chains, which are generated 
by RNF8 suggesting that there is a K63-independent DNA damage response that involves 
VCP and possibly USP50. The interaction between USP50 and VCP has not yet been 
studied but the known cleavage ability of the VCP complex on K48-chains, and the 
evidence that USP50 depleted cells show a decreased level of polyubiquitin chains and an 
increase in H2AX, is intriguing.  
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Aims of the project 
The overall target of this project was to learn more about USP50. The specific aims were as 
follows:- 
1. Use bioinformatic resources to analyse human USP50 to develop an understanding 
of its structure and function. Also to investigate the evolutionary origin and changes 
within the gene in reference to its molecular domains and function. 
2. Using fluorescence microscopy to examine the localisation of USP50 with and 
without damaging agents. 
3. Using the structural predictions and functions, generate mutated and wild type 
USP50 vector constructs to make a stable induced-expression cell lines.   
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METHODS 
Unless otherwise stated chemicals and tissue culture supplies were obtained from Sigma (St 
Louis, MO, USA) and Corning (Corning, NY, USA), respectively. 
Materials 
DNA 
GFP-USP50 plasmid was obtained from OriGene (Rockville, MD, USA) 
GFP plasmid was obtained from Clontech Laboratories Inc (Mountain View, CA, USA) 
Primers 
Primer structure as detailed in protocol. All primers obtained from Sigma-Aldrich (St 
Louis, MO, USA)  
Antibodies 
Murine anti-phosphorylated S138 (ɣH2AX) was obtained from Abcam (Cambridge, UK) 
Alexafluor 555 goat anti-mouse was obtained from DAKO (Glostrup, Denmark) 
Hoechst was obtained from Sigma (St Louis, MO, USA) 
Restriction Enzymes 
Restriction enzymes (BamH1 and EcoR1) were obtained from New England Biolabs 
(Ipswich, MA, USA) 
Solutions 
Triton - 
0.2% Triton in 1x PBS 
Sucrose solution- 
100 mM NaCl,  
300 mM sucrose,  
3 mM MgCl2,  
10 mM Pipes [pH 6.8], 
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 1 mM EGTA,  
0.2% Triton X-100 
1x Phosphatase inhibitor tablet 
1x Protease inhibitor tablet 
HEPES-NP40 buffer- 
20mM HEPES pH 7.5 
20mM NaCl 
5mM MgCl2 
1mM DTT 
0.5% NP-40 
1x Phosphatase inhibitor tablet 
1x Protease inhibitor tablet 
10mM iodoacetamide  
 
Protocols 
Tissue Culture 
Cells were maintained in DMEM with 10% FCS and Penicillin/Streptomycin and grown at 
37°C, 5% CO₂. Passages were done regularly depending on cell confluence. When cells 
reached 50% they were passaged following trypsinization at a 3:10 dilution but cells that 
reached 80% confluence were passaged at a 1:10 dilution.  
Transfection protocol 
Cells were plated into 24 well plates 24 hours before transfection. The FuGene 6 (Roche, 
Indianapolis, IN, USA) protocol was used. 
SFM (OptiMem (Invitrogen, Grand Island, NY, USA)) was added to each eppendorf before 
FuGene 6 was added in the quantities in the following table. The eppendorf was mixed by 
flicking the tube a few times and left at room temperature (RT) for 5mins. The appropriate 
DNA was added and vortexed for one second. The mix was left at RT for 20mins and 
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100µl was added to each well without removing the media. Cells were stored in the 
incubator for 24 or 48 hours before being treated with IR then fixed and stained.  
Solution Quantity per well 
OptiMem 96µL 
FuGene 6 4µL 
DNA (100nM/µL) 1µL 
Table 2- FuGene protocol quantities 
Irradiation of cells 
Cells were irradiated in immunofluorescence protocols with 2Gy of IR. Cells that were not 
irradiated were removed from the incubator and subjected to the same treatment except for 
the irradiation. 
Immunofluorescence microscopy protocol. 
Cells were plated into 24 well plates with coverslips approximately 24 hours before 
transfection of USP50-GFP, GFP or were not transfected as a control.  
Cells were fixed and permeabilised in one of the following ways; PFA/Triton, Sucrose 
solution, Methanol and HEPES-NP40 buffer. Each technique is as follows:- 
PFA/Triton- 
Cells were fixed for 10mins with PFA (4%) at RT and washed with PBS. Cells were 
permeabilised using 0.2% Triton/PBS solution for 10mins at RT and washed with PBS.  
Sucrose solution- 
Cells were placed on ice and treated with sucrose solution for 5mins to fix and 
permeabilise. Cells were washed with PBS. 
Methanol- 
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Cells were fixed and permeabilised by treating with -20°C Methanol for 3mins and air 
dried. 
HEPES-NP40 buffer- 
Cells were treated with HEPES-NP40 buffer to fix and permeabilise and washed with PBS. 
 
Cells were either stored in PBS at 4°C overnight or stained immediately as follows. All 
cells were fixed with PFA (4%) for 20mins at RT prior to staining. After washing with 
PBS, 10% FCS/PBS was added to block for 10mins and washed with PBS.  
The primary antibody was added at RT for one hour. The primary antibody was 
phosphorylated S138 mouse anti-H2AX at a dilution of 1:5000 in 10% FCS/PBS. After 
staining the cells were washed twice with PBS. 
The secondary antibody was added at RT for one hour. The secondary antibody was red 
goat anti-mouse at a dilution of 1:2000 in 10% FCS/PBS. After staining the cells were 
washed twice with PBS. 
Cells were stained with Hoechst/PBS solution for 2mins at RT and washed twice with PBS. 
Cells were fixed again with PFA (4%) for 10mins. 
The cells were then mounted onto slides with Dako Fluorescence Mounting Medium 
DAKO (Glostrup, Denmark) and coverslips were sealed with clear nail varnish. Slides were 
stored at 4°C in the dark until assessed with a microscope. 
The two cell localisation experiments had different protocols. The cell localisation 
experiment involved all of the previously mentioned fixing and permealibisation techniques 
and the time course cell localisation experiment involved only the PFA/Triton protocol.  
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Restriction Digest 
This protocol was used to digest the DNA constructs for ligation into expression vectors. 
The following solutions were made in the stated quantities and put in a 37°C incubator for 
2 hours.  
Solution Double Digest Single Digest 1 Single Digest 2 Uncut 
Xho1 1µL 1µL 0 0 
BamH1 1µL 0 1µL 0 
Buffer x10 1µL 1µL 1µL 1µL 
BSA (10x) 1µL 1µL 1µL 1µL 
DNA 2µL 2µL 2µL 2µL 
dH₂O 4µL 5µL 5µL 6µL 
Total 10µL 10µL 10µL 10µL 
Table 3- Restriction digest protocol quantities 
Primers 
Several constructs were made to examine the functional regions of USP50. The following 
primers were used the following standard PCR reaction using Phusion (Fermentas, St. 
Leon-Rot, Germany) polymerase.  
Primers for USP50-USP8-tail construct 
Usp50_8_tail_F GAATTCAGTCACCCAGGCCTGGTTTAAGTTTGATGATCATGAA
GTTTCTGATATCTCCGTTTCTTCTGTGAAATCTTCAG 
Usp50_8_tail_R TTCTCGAGTTATGTGGCTACATCAGTTACTCGTGGTCCCAATG
AAGTATAAAAGAGGATATAAGCTGCTGAAGATTTCAC 
Primers at the start and end of USP50 
pET_F_BamH 
(Start primer for 
pET28a) 
ATGGGTCGCGGATCCTTTACTTCTCAGCCGTCTCTCC 
pc5_F_Bam_flag_5
0 (Start primer for 
pcDNA5) 
GATCCGGATCCATGGATTATAAAGACCATGACGGAGATTATA
AAGATCACGACATCGACTACAAGGATGACGATGACAAG 
pC5_R_Xho_50 
(End primer 
suitable for both 
vectors) 
ATTCTCGAGCTCGAGCTAGGCCTGGGTGACTGAATTCTTGC 
Primers to create deletions 1 and 2 
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186_Rev_50_del1 CAGCTCTTGGCAACCTCTATCCGGCTTTTACG
AAAAAGATGCAACAAG 
203_Fwd_50_del1 CCCAGCTGTTTGAAGAGCAGCTCAATGTCTT
CACTGTCTTCTCACTCCCC 
236_Rev_50_del2 GTTGTTCCAGGTCAGTGCG 
253_Fwd_50_del2 CGCACTGACCTGGAACAACGCCAGTATTTCC
AAAGCACC 
Table 4- Primer names and sequences 
Cloning and PCR 
Solution Quantity per well 
5x PCR buffer 10µl 
4M Betaine 10µl 
20µM dNTPs 0.5µl 
Phusion enzyme 0.5µl 
20µl Forward primer 2µl 
20µl Reverse primer 2µl 
100nM Template DNA 1µl 
dH₂O 24µl 
Total 50µl 
Table 5- PCR protocol quantities 
PCR programme 
The denaturing step was 95°C for 30 seconds (s). The annealing temperature was based on 
the lowest of the primers which was 42°C for 30s. The elongation temperature was 72°C 
for 3 mins for the first step of making the constructs and 5 mins for all other steps of PCR 
that were needed to make the full length USP50 constructs. This cycle was repeated 30 
times and kept at 72°C for 10 mins. Reactions were stored until use at 4°C. 
The constructs were made for between 8-10 tubes per reaction to make bulk of each 
construct. The controls for each PCR were one sample with no DNA, one sample with only 
the forward primer and one sample with only the reverse primer. 
Agarose gel (1%) and gel electrophoresis 
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TAEx1 Buffer 250ml 
Agarose powder 2.5g 
Ethidium Bromide 2.5µL 
Table 6- Agarose gel recipe quantities 
TAEx1 buffer and Agarose, as listed above, were added to a conical flask and heated until 
the agarose melted. Once partially cooled, Ethidium Bromide was added and poured into a 
prepared gel mould with combs. The gel was left to set and placed into a gel electrophoresis 
tank in TAE running buffer. The gel was run at 130V and run until the bands separated.  
Gel purification 
Gel purification experiments followed the QIAGEN® QIAquick Gel Extraction Kit 
protocol (September 2010). 
Phenol: Chloroform clean up 
200µL of Phenol Chloroform solution was added to 200µL of DNA construct solution. 
They were vortexed for 10s and microcentrifuged for 15mins at 13,000 rpm at RT. The top 
layer from the centrifuged tubes was added to a new eppendorf and 10% of 3M sodium 
acetate (C2H3NaO2) was added and vortexed. The samples had 100% ethanol added to the 
eppendorf (2.5 x (C2H3NaO2 + sample)µL). The samples were centrifuged for 15 mins at 
13,000 rpm at RT and the supernatant was discarded. 1ml of 70% Ethanol was added to the 
samples before centrifuging at 13,000 rpm for 25 mins. The supernatant was removed and 
the eppendorf was left to dry before resuspending in 10µL of deionised water.  
Bioinformatics site uses 
NCBI BLAST, iTOL and CCDS were used to search the nucleotide sequences of USP50 
and USP8 and the results were used for figures.  
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The Ensembl Project website was used to search for either USP50 or USP8 and information 
was used for figures. 
SwissPDB website was used to predict the structural model of USP50 and USP8. 
SwissPDB Viewer was used to visualise the downloaded structural models and to overlay 
the structures.  
The Interactive Tree of Life (iTOL) was used to create phylogenetic trees of USP50 from 
various species. 
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RESULTS 
The domains and active sites of USP50  
As previously mentioned, USP50 has not been studied in great detail and to understand its 
functionality, or lack of, more analysis was needed into the gene origin, the genomic 
location and protein structure and domains.  
The nucleotide sequence of USP50 was searched using the NCBI BLAST database 
(Camacho et al., 2009) which predicted the domains and active site in USP50 
(Supplementary Figure 1). The UCH domain (DUB catalytic domain) maps from aa41-334 
and the active site residues are located at aa47 and 322. The nucleotide search found other 
genes that showed similarity or conserved regions to USP50. The gene with the highest 
similarity in sequence was USP8.  
USP8 was also searched using the NCBI BLAST database (Supplementary Figure 2), USP8 
gene is larger than USP50 and they share a UCH domain and the active site. USP8 possess 
two active sites which are a DUF1873 superfamily domain and a RHOD superfamily 
domain.  
The amino acid sequences for USP8 and USP50 were aligned using NCBI BLAST and 
CCDS (Camacho et al., 2009; Pruitt et al., 2009) and the conserved domains containing the 
active site and catalytic residues were mapped (Supplementary Figure 3). The third residue 
of the catalytic triad (aspartate residue) is missing from USP50 as the C-terminal end of 
USP50 is truncated. The truncated region of USP50 and its correlating region in USP8 will 
be referred to as the ‘tail’ region for simplicity. USP50 lacks one of the catalytic residues of 
the protein therefore is predicted not to possess deubiquitinase activity (Nijman et al., 
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2005). Figure 2 shows the alignment of USP50 against USP8 from the catalytic histidine 
residue to the aspartate residue. It shows the single nucleotide change that caused the stop 
codon which truncates USP50. A single mutation would remove the stop codon and 
produce a protein product that contains an aspartate residue that would complete the active 
site. 
 
The evolutionary relationship between USP50 and USP8 
The USP50 gene was searched using The Ensembl Project website (Flicek et al., 2012). 
USP50 is located on human chromosome 15 (chr15) (Supplementary Figure 4). Strikingly, 
USP50 is located next to USP8 on chr15. USP8 is transcribed from the forward strand and 
USP50 transcribes from the reverse strand, with a slight overlap of the end of the gene 
sequences (Figure 3). The high similarity of sequence between USP8 and USP50, and the 
positioning on chr15, suggests that they may have originated from a single ancestral gene 
that has been duplicated and has diverged. This is supported by Ye et al, who studied the 
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relationship 
between of human 
and yeast USP 
enzymes produced 
a phylogenetic 
tree showing 
USP50 is closely 
related to USP8 
(Ye et al., 2009).  
The chromosomal 
positioning of USP8 and USP50 were compared between humans and mice (Figure 3 and 
Supplementary Figure 5). USP50 and USP8 are on the same chromosome in mice and are 
on opposing strands, but the overlap of USP50 and USP8 is greater on the mouse chr2 than 
the human chr15. This is suggestive of a small lengthening of the DNA that caused human 
USP50 and USP8 to overlap less.  
In orangutans USP50 and USP8 have a similar degree of overlap of USP50 and USP8 in 
humans (Figure 3). In other species such as the anole lizard, USP50 and USP8 do not 
overlap but are still on opposing strands and adjacent on the same chromosome. In cows, 
USP8 and USP50 are both on chr10 and in opposing directions, but USP50 is on the 
forward strand and USP8 is on the reverse strand (Figure 3). The comparison between 
species shows that this part of the genome has seen several changes in structure through 
evolution because of the various positions of USP8 and USP50.  
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USP50 orthologs are not present in all chordates but are found in mammals, lizards and 
arthropods (Figure 4 and Supplementary Figure 6) (Camacho et al., 2009). USP8 has 
homology in species which diverge as far back as yeast (Flicek et al., 2012; Pruitt et al., 
2009) (TreeFam.org, TF106277, data not shown). This would suggest that USP50 is a 
paralog of USP8 that was duplicated at the level of chordate divergence. 
 
The ‘tail’ region truncation of USP50 
The ‘tail’ region is absent at the protein level in USP50 in many species but present in 
USP8 and some orthologs of USP50. The presence of the truncation in multiple species 
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confirms the human USP50 sequence truncation is valid and not due to a sequencing error. 
To locate the ancestral lineage point where the truncation occurs, the conserved regions of 
USP50 from all species were aligned and the catalytic trial residues were labelled to 
separate the orthologs into those with and without the catalytic aspartate residue (Figure 4, 
Supplementary Figure 6 & 7). There was no alignment on a phylogenetic tree of the ‘tail’ 
region sequence suggesting that there was not a single evolutionary event followed by 
divergence that truncated the ‘tail’ of USP50, as species known to be ancestrally close did 
not align closer together 
(Supplementary Figure 8). 
This data suggests the 
truncation event has 
occurred in multiple 
species. 
The structure of USP50 
and USP8 
SwissPDB was used to 
predict the structure of 
USP50 as USP50 protein 
has not been identified. The 
amino acid sequence of 
USP50 was threaded on to 
the known structure of the 
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catalytic domain of USP8 (PDB: P40818) (Figure 5 & Supplementary Figure 9) 
(Avvakumov et al., 2006).  
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The structure of USP50 was modelled and labelled with catalytic residues, associated non-
essential glycine residue and the final amino acid: to highlight where the truncation occurs  
Figure 5 and Supplementary Figure 9). USP50 prediction and USP8 were overlaid to 
compare the two active sites and two tail structures (Figure 5), the combined structures 
shows the USP8 tail curves back to place the aspartate residue in the active site and that 
without the tail the active site is more open. Other DUBs have conformational changes that 
move the tail region which realigns the catalytic domain (Hu et al., 2002). Considering this, 
the missing catalytic residue and the truncation of the tail may have an additive effect on 
the predicted inactivity of USP50.  
To examine the relationship with ubiquitin in more detail the positioning of ubiquitin in the 
active site was predicted using structural models of DUBs binding to ubiquitin and crystal 
structures of DUBs that were isolated bound with ubiquitin, such as USP14 (Borodovsky et 
al., 2001), HAUSP (Hu et al., 2002) and USP2 (Renatus et al., 2006).  Figure 6a shows the 
overlaid USP50 and USP8 at an angle where the finger structural region is visible. 
Ubiquitin (modelled from USP14 (Borodovsky et al., 2001) and ubiquitin crystal structure, 
PDB: 2AYO) (Figure 6b) sits in the middle of the structure with its tail region passing 
between the palm and thumb into the active site (Figure 6c). USP50 is highlighted with the 
catalytic residues of the active site where ubiquitin is predicted to bind, which is analogous 
to ‘holding ubiquitin in the palm of a hand’ (Figure 6 & Supplementary Figure 10) (Ye et 
al., 2009).  
The modelled structure of ubiquitin and USP50 predicts, that when ubiquitin binds, the 
ubiquitin tail protrudes into the catalytic triad (Figure 7a) where it lies between the cysteine 
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and histidine residue, but when USP8 is overlaid (Figure 7b) the difference in the tail 
structure directly around the active site, can be seen (This model has been rotated in 
Supplementary Figure 11 to show the ubiquitin tail in the centre of the catalytic triad). The 
tail can be seen to provide a curl of protein 
that covers the active site. The curl 
structure of β-sheet-turn-β-sheet, on which 
the aspartate residue is located, covers the 
open side of the protein. Figure 8 is a 
planar view of the active site in USP8 and 
shows the distance between the side chains 
of the catalytic triad and the ubiquitin tail. 
From this analysis into the structural 
positioning of the catalytic triad and the 
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‘tail’ region of USP8 and USP50 (Camacho et al., 2009), we suggest that if the ‘tail’ region 
of the USP8 protein were to be attached to the end of USP50 protein then the function of 
USP50 may be altered due to the restoration of the catalytic triad and any supportive 
element the ‘tail’ structure may 
provide.  
The model of USP50 and 
ubiquitin suggests that ubiquitin 
interacts with the finger regions 
of DUBs and certain residues on 
the fingers are highly conserved 
for this reason (Hu et al., 2002). 
A mutation in the finger regions 
of USP50 could influence the binding ability of ubiquitin and the conserved finger regions 
in USP50 could be deleted using two deletions from aa186-203 and 236-253 (Figure 9 & 
Supplementary Figure 12 a&b).  
Localisation of USP50 in U20S cell line 
Very little is known about USP50 localisation in cells and two previous attempts to create 
constitutively USP50-GFP expressing cell lines failed. They showed abnormally high 
levels of cell defects. Aressy et al, suggested that USP50 translocates from the cytoplasm to 
the nucleus upon DNA damage (Aressy et al., 2010). To investigate this further; U20S cells 
were transfected either USP50-GFP or GFP vector. 16 hours after transfection cells were 
irradiated, or left unirradiated and were fixed and permeabilised using various buffers 
(HEPES-NP40 buffer, Sucrose buffer, Methanol or PFA/Triton method). First cells were 
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incubated with murine anti-phosphorylated S138 (γH2AX) antibody and Alexafluor 555 
goat anti-mouse antibody, and counterstained with Hoechst to visualise DNA. Cells 
expressing GFP were counted (n=100) and the cellular localisations (Supplementary Figure 
13), and number of GFP expressing cells showing karyorrhexis (breaking up of the nucleus, 
characteristic of cells undergoing apoptosis), was recorded and are shown in Supplementary 
Figure 14. The number of GFP positive cells showing karyorrhexis were counted due to 
previous cell death seen in cells overexpressing USP50.  
The localisation of GFP expression was spread evenly throughout the cytoplasm and 
nucleus in GFP-transfected cells and there was no difference between irradiated cells and 
non-irradiated. The USP50-GFP was mainly expressed in the cytoplasm, but also showed 
pancellular localisation. The cells with USP50-GFP expression throughout the cell did 
increase on irradiation but not significantly. The level of karyorrhexis in irradiated GFP 
transfected cells was 
higher than in the non-
irradiated, however 
this was converse in 
the USP50-GFP 
transfected cells. 
A time course 
experiment was used 
to examine cell 
localisation of USP50-
GFP and GFP in U20S cells that were transfected with GFP or USP50-GFP. Cell were 
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separately irradiated at 16, 40 and 64 hours after transfection, then fixed and permeablised. 
GFP positive cells, in comparison to background levels of fluorescence, were scored for 
cellular localisation and the presence of karyorrhexis (Figure 10).  
Predominantly the localisation of GFP and USP50-GFP was identical to the previous 
experiment but the level of cells showing karyorrhexis rose with the length of time after 
transfection. The percentage of karyorrhexis for each time point was higher in USP50-GFP 
transfected cells than the GFP transfected cells. In the 40 and 64 hour experiments, there 
were more GFP-positive cells showing karyorrhexis that unirradiated than in irradiated 
cells (Figure 11). GFP transfected cells in all time course experiments showed irradiated 
cells to have higher levels of nuclear defects.  
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These experiments suggest that USP50 expression is damaging to the cells and that USP50-
GFP non-irradiated cells are more defective than irradiated, which in converse to what 
would be expected and what is seen in the GFP transfected cells. This data shows a small 
amount of pancellular USP50 localisation which increase on irradiation, but not comparable 
to the literature (Aressy et al., 2010). 
Cloning USP50 mutants 
From these observations, we decided to clone several mutant versions of USP50 into 
inducible expression vectors to create the expression of USP50 in an induced and titratable 
manner, and to test the structural mutants identified in the analysis with USP8. In addition, 
cloning products were designed to incorporate the tail of USP8 onto USP50. Stable 
inducible cell lines will allow USP50 to be expressed in human cells without causing the 
cellular defects and death that made USP50 effects difficult to measure in the cellular 
localisation experiments.  
Previous studies exmaining the binding of ubiquitin and USP enzymes have identified 
regions in the finger structures and between the thumb and palm that are conserved and 
hydrophobic (Hu et al., 2002). The hydrophobic nature of these areas is interesting as they 
are on the open side of the protein, and in most proteins this is considered to be a possible 
interaction site as hydrophobic residues will bind more readily to other proteins than 
hydrophilic residues. There are two hydrophobic regions in USP50 similar to USP 
enzymes, and we considered that deletion of these regions may affect USP50’s ability to 
bind to ubiquitin. These conserved finger regions are shown in Figure 9. These regions 
range from amino acid (aa) 186-203 and 236-253. The second set of cloning products 
involved deleting the two predicted hydrophobic ubiquitin interacting regions of USP50. 
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Deletion 1 ranges from aa 186-203 and 
deletion 2 ranges from 236-253. Finally, two 
full length wild-type USP50 cloning products 
were for control purposes and to create stable 
cell lines. The pcDNA5/FRT/TO vector was 
utilised because it is an inducible expression 
vector. 
After each PCR step, products were subjected to electrophoresis with controls, to check the 
size. The correct sized bands were then excised and purified. The purified product was 
analysed by electrophoresis to confirm size, purification and presence before continuing 
with the next PCR cloning stage (Supplementary Figure 18 & 19).  
The two full length (FL) cloning products were created using the vector specific forward 
primers (pET_BamH1_Fwd and pc5_Flag_Fwd) with the USP50 reverse primer 
(pc5_Xho1_Rev) 
(Figure 12 & 
Supplementary 
Figure 15).  
The USP50/8 tail 
cloning products 
(Figure 13 & 
Supplementary 
Figure 16) were 
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made using the USP50_8_Tail_Fwd primer and USP50_8_Tail_Rev primer which creates a 
fragment of the end of USP50 and the USP8 tail (Supplementary Figure 18). This was 
termed USP50_8 Tail and used as a primer with the vector specific forward primers and 
USP50_8_Tail_Rev to create USP50 with the added USP8 tail region (Supplementary 
Figure 19).  
The USP50 deletions were created in two stages using overlapping primers (Figure 14 & 
Supplementary 17). Firstly, the fragment before the deleted region was created, using the 
vector specific forward primers and either the 186_Rev or the 236_Rev primer. Secondly, 
the fragment after the deleted region was created using the USP50 reverse primer and the 
203_Fwd or 253_Fwd primer. The primers were designed to overlap to bridge the gap over 
the deleted region, and used to create products of USP50 with either deletion 1 (aa186-203) 
or deletion 2 (aa236-253).  
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Both forward primer sequences include BamH1 site and the 5’ coding region of USP50. 
The pc5_Flag_Fwd primer also includes 3x FLAG tag sequences to allow the low 
expression of USP50 to be better visualised in cells. The pET_BamH1_Fwd vector was 
used with USP50-GFP to include GFP labelled USP50 into the cloning product. 
pc5_Xho1_Rev primer sequence covers the 3’ end of USP50 and incorporates a Xho1 
restriction enzyme site. These primers were used with either USP50-GFP or Flag-USP50 
cDNA in a PCR to synthesize the USP50 cloning products 
The final cloning products were amplified using PCR and cleaned up with 
Phenol:Chloroform. The cloning products and vector DNA were digested using Xho1 and 
BamH1 and cleaned up by Phenol:Chloroform. The samples and vectors, including 
experimental controls, were electrophoresed to check for their presence (Supplementary 
Figure 20 & 21). The success of the cloning products at each stage are detailed in Table 7.  
The PCR products successfully made were; pET control USP50, pc5 USP50_8 Tail, pET 
USP50 Deletion 1 and pc5 USP50 Deletion 1 (Supplementary Table 1). 
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DISCUSSION 
The bioinformatics investigation of USP50 has shown that it is closely related to USP8, 
USP50 is truncated by a stop codon that causes loss of a catalytic residue in its UCH 
domain and has identified the finger regions of USP50 as being involved in ubiquitin 
binding. The cell localisation experiments have shown that USP50 mainly localises to the 
cytoplasm, and there was an increased rate of karyorrhexis in USP50 transfected cells 
compared with controls. Surprisingly, there is less karyorrhexis in cells that have been 
irradiated than unirradiated cells.  
The early literature that identified all known DUBs suggested that USP50 is catalytically 
inactive due to the loss of the Asn/Asp residue of the catalytic triad. However, Aressy et al 
2010 suggests USP50 associates with G2/M cell cycle checkpoint signalling proteins. 
USP50 stabilizes HSP90, allowing Wee1 to activate the G2/M checkpoint through 
CDC25B. When USP50 is depleted, illegitimate entry to mitosis increased ~1.5 fold. This 
could explain the high levels of nuclear karyorrhexis that is seen over time in the cellular 
localisation experiments. Without accurate G2/M checkpoint signalling, cells continue into 
mitosis with DNA damage, and this causes aberrant segregation in mitosis, DNA defects 
and karyorrhexis. This leads to micronuclei formation and through several cell cycles 
would lead to mitotic catastrophe. This DNA damage and cell death would be expected to 
be greater in cells treated with IR. The evidence from Aressy ((Aressy et al., 2010) and the 
data shown here, suggests that USP50 is functional but may not be an active 
deubiquitinase. 
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Aressy et al, shows USP50 relocating to the nucleus after damage. Although our cellular 
localisation experiments could not reproduce the same results at identical levels of IR, it is 
likely that it does relocate because of its function with HSP90 in G2/M cell cycle 
checkpoint which occurs in the nucleus. The association with the G2/M checkpoint 
signalling and the alteration of the quantity of ubiquitin chains after DSB induction 
suggests evidence that USP50 is either present in the nucleus, even without containing 
known nuclear import sequences, or regulating nuclear factors that orchestrate these effects. 
However, when looking at the interactors of USP50, the 11
th
 most potent interactor is 
nucleoporin 214kDa (NUP214), a nucleopore complex protein that is part of a nucleoporin 
subcomplex. This could explain how USP50 relocates into the nucleus and further research 
using NUP214 overexpression may show an increase in USP50 in the nucleus. 
VCP was found to be in the top ten interactors of USP50. VCP is needed for Rad51 
accumulation which is crucial for replication fork restart and HR, so without VCP 
replication forks would collapse into DSB and HR would be faulty. The increase in ɣH2AX 
signal without damage when USP50 is depleted, may be due to not resoluting DSBs due to 
the alteration of ubiquitin chains, this could be indicative of spontaneous damage or of 
aberrant DDR signalling. The loss of Rad51 loading due to faulty VCP would lead to an 
increase in ɣH2AX signal without DNA damage in replicating cells. This could indicate 
that USP50’s interaction with VCP may be involved in Rad51 accumulation. 
The overexpression of USP50 may also affect its’ activity in the DSB response. It could 
cause an overprotection of ubiquitin chains and this may cause persistent repair protein 
accumulation and delay damage repair. Interestingly, levels of karyorrhexis is lower in cells 
that had been irradiated compared to those that were not irradiated, which is opposed to 
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what was seen in the control GFP cells. This could be that the overexpression of USP50 in 
irradiated cells is less toxic because it is active in DNA repair or cell cycle checkpoint 
signalling, which is not active in unirradiated cells. 
The polyubiquitin signal reduction on USP50 depletion suggests that USP50 may have a 
protective role with ubiquitin chains at sites of DNA damage, as it does not appear to 
cleave ubiquitin linkage bonds. The finger deletion constructs will identify if they are 
important in USP50 for binding to ubiquitin and could suggest the catalytic domain may 
not be essential for ubiquitin binding. The USP50 construct with USP8 tail will be able to 
identify if restoring the catalytic domain allows deubiquitinase activity or changes the 
binding activity to ubiquitin. 
It would be interesting to investigate the binding region on USP50 that interacts to stabilise 
HSP90 as USP8, USP50’s evolutionary homologue, also functions to stabilize NRDP1, an 
E3 ligase. It would be interesting to see if USP50 interacted and stabilised an E3 ligase like 
USP8, as it is involved in protecting ubiquitin chains.  
The binding partners and similar functions of USP50 and USP8 could provide more 
evidence on the coevolution of DUBs and their specific substrates, considering that both 
USP50 and USP8 are known to function by stabilising a substrate to enable its function and 
they are very closely related genes. USP50 is smaller than USP8 and several domains are 
missing, it would be interesting to see which domains link to which functions in both USP8 
and USP50. This could lead to a more in depth study to exactly how the changes from 
USP8 to USP50 adapt to serve a new function separate to USP8’s activity.  
It is difficult to predict, on such little evidence how USP50 directly acts in the DSB repair 
pathway. One idea is that the reduction in FK2 signal is indicative of less polyubiquitin 
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chains accumulating after damage suggesting USP50 has a protective role on the ubiquitin 
chains. VCP is an interactor of USP50 and is associated with a RNF8-dependent, RNF168-
independent DSB repair pathway that is associated with Rad51 recruitment. It is the VCP 
complex that is needed for K48 chain removal, which allows K63 chain elongation and this 
recruits HR proteins such as BRCA1. If USP50 protects K48 chains then when USP50 is 
depleted, VCP would decrease K48 chains and K63 chains would accumulate, therefore 
still producing a FK2 signal. If USP50 protects K63 chains then the depletion would not 
affect the removal of K48 chains, but also would not prevent the K63 chains from being 
degraded. This later theory would show an overall decrease in FK2 signal, which is what 
we see in USP50 siRNA depletion. The interaction between USP50 and VCP could be the 
link between K48 chain depletion signalling K63 chain elongation.  
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THE ROLE OF BRCA1 AT STALLED REPLICATION 
FORKS 
ABSTRACT 
BRCA1 is a common inherited mutation in families with early onset breast and ovarian 
cancer. Cancers with homozygous mutations in BRCA1 are more resistant to chemotherapy 
due to abnormal DNA repair. Gemcitabine is a DNA replication inhibitor used to treat 
breast and ovarian cancer. How cancer mutations change the response of cells is poorly 
understood. Here, we investigate how BRCA1 mutations effect response to Gemcitabine 
using the cell line, HCC1937. BRCA1-proficient and –deficient cells were used to 
investigate the replication fork stalling, fork restart, 53BP1 and ɣH2AX foci, phospho-RPA 
levels, cell cycle accumulation and clonogenic survival after Gemcitabine treatment. 
Techniques utilised included DNA fibre analysis, immunofluorescent staining, FACS, 
Western blot and clonogenic survival assays.  
BRCA1-deficient cells display increased fork stalling and earlier induction of phospho-
RPA, 53BP1 and ɣH2AX. BRCA1 status effects the accumulation of cells in S phase after 
Gemcitabine treatment. BRCA1-deficient cells show decreased survival to <10µM 
Gemcitabine treatment.  
We report that BRCA1 protects slowed and stalled forks, and prevents forks collapsing into 
double-strand breaks. BRCA1 status affects the sensitivity of cells to Gemcitabine 
treatment.  
 
Word Count: 7304 words 
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INTRODUCTION 
DNA replication  
For cells to replicate and divide, they need to create an exact copy of their genome to semi-
conservatively pass on to daughter cells. However, DNA can become damaged through 
internal and external influences. Therefore, cells have evolved to have high fidelity DNA 
replication methods, complementary DNA repair mechanisms, and cell cycle checkpoints 
to ensure DNA damage is not inherited. If the damage is too great, cells will undergo cell 
death.  
In carcinogenic cells, genes that control these processes are often mutated and many genetic 
diseases with high rates of cancer have been linked to mutations in these genes, i.e. 
BRCA1, BRCA2, and ATM. Many cancer therapies target the proteins that control cell 
cycle, DNA damage repair, and DNA replication to force cells into cell death. Therefore it 
is important to study the molecular basis of replication to have the potential to create 
effective DNA replication targeting cancer therapies.  
In eukaryotes, there are approximately 20,000 origins of replication called ‘initiation 
regions’ (Mechali, 2001) which are DNA sequence independent (Vashee et al., 2003). The 
ORC (origin recognition complex) is a 6 subunit complex which binds to ORC binding 
sites at origins of replication (Bell and Stillman, 1992), which forms the pre-replication 
complex with CDC6 (cell division cycle 6) (Bell et al., 1995), CDT1 (chromatin licensing 
and DNA replication factor 1) (Nishitani et al., 2000) and the MCM (mini-chromosome 
maintenance) helicase complex (Tanaka and Diffley, 2002; Tanaka et al., 1997). ORC1 
binding can only occur in G1 (Li et al., 2004) because of the absence of CDC6 due to 
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exportation out of the nucleus after phosphorylation by CDK1-cyclin A (Pelizon et al., 
2000). The pre-replication complex is phosphorylated in early S-phase by cyclin E CDK2 
(cyclin-dependent kinase 2) (Krude et al., 1997) and DDK (Dbf4/Drf1-dependent CDC7 
kinase) (Lei et al., 1997), this allows the recruitment of CDC45 (Mimura and Takisawa, 
1998) and the GINS (go-ichi-ni-san) complex (Takayama et al., 2003) to promote origin 
firing (Gambus et al., 2006; Ilves et al., 2010). Dbf4 which activates DDK is degraded by 
the proteasome in G1 phase (Sclafani, 2000). When both CDK and DDK pathways are 
inhibited, the DNA replication is arrested in G1 phase (Zegerman and Diffley, 2007). 
MCM proteins 2-7 form a hexamer that binds CDC45 to form the MCM complex, which 
unwinds the DNA strands (Pacek and Walter, 2004). The helicase activity of the MCM 
complex is ATP-dependent (Pacek and Walter, 2004) and any single-stranded DNA 
(ssDNA) that is exposed is coated by RPA (replication protein A) (Brill and Stillman, 1989; 
Erdile et al., 1991). 
The machinery that forms the replisome include the MCM complex, RFC (replication 
factor C) (Tsurimoto and Stillman, 1989), PCNA (proliferating cell nuclear antigen), DNA 
polymerases (Tsurimoto and Stillman, 1991), and GINS, which maintains the replisome 
structure (Gambus et al., 2006; Pacek and Walter, 2004). RFC is a clamp loader that loads 
PCNA, the DNA polymerase clamp which encircles DNA in a trimeric ring structure (Lee 
et al., 1991). It is PCNA that binds DNA and recruits polymerases α-primase, pol δ and pol 
ε to the replisome (Stukenberg et al., 1991; Tsurimoto and Stillman, 1991). Polymerase α-
primase forms an 8-12 nucleotide (nt) RNA primer (Matsumoto et al., 1990) which is 
elongated by pol δ with ~40 DNA nt (Nethanel et al., 1988). This is called the RNA-DNA 
primer and it is created once on the leading strand and at the beginning of all Okazaki 
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fragments on the lagging strand (Murakami et al., 1992). The synthesis of DNA is carried 
out by pol δ on the lagging strand and pol ε on the leading strand (Tsurimoto and Stillman, 
1991; Tsurimoto et al., 1990) and is regulated by RFC and PCNA (Tsurimoto and Stillman, 
1991). RFC and PCNA allow FEN1 (flap endonuclease 1) and DNA ligase I to access 
Okazaki fragments. Once Okazaki fragments have been synthesized the primer needs to be 
removed from the strand. FEN1 and pol δ, together at the end of the Okazaki fragment, 
degrade the primer by causing dissociation from the parental DNA strand to become a flap 
of nucleotides which is then removed by FEN1 (Murante et al., 1996; Turchi et al., 1994). 
Pol δ extends the DNA to the next Okazaki fragment and DNA ligase I anneals between the 
two (Turchi and Bambara, 1993).  
The mechanism of replication termination in eukaryotes is unclear but from studies in 
Xenopus, termination appears to occur where two replication forks meet each other and not 
at a specific location or sequence (Santamaría et al., 2000).  
Fork stalling and replication restart 
During DNA replication, there can be obstacles that the replisome needs to overcome to 
complete synthesis of the genome. These obstacles slow down or stop replication fork 
progression known as fork stalling. There are various types of obstacles that can cause 
stalled forks, such as ribosomal barriers (Brewer and Fangman, 1988), unusual DNA 
structures (Lobachev, Rattray and Narayanan, 2007), checkpoint proteins (Katou et al., 
2003), DNA damage, fragile chromosomal regions (Subramanian, Nelson and Chinault, 
1996), insufficient dNTPs (Odsbu et al., 2009) and transcription-replication collisions 
(Brewer and Fangman, 1988).  
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Stalled forks can remain stationary for many hours until, after inactivation, they collapse 
into double-strand breaks (DSBs). The DSBs created by fork collapse are generated by the 
endonuclease complex of MUS81 (MUS81 endonuclease) (Hanada et al., 2007) and EME1 
(essential meiotic endonuclease 1 homologue 1) (Boddy et al., 2001). If the stalled fork is 
resolved, fork restart can occur. It has become apparent that there are various proteins that 
are associated with the stabilization of the stalled fork and can influence the length of time 
before stalled forks become DSBs. 
Replication stalling, through these obstacles, has facilitated the development of 
chemotherapeutics that stall forks indefinitely, or until forks become DSBs. Examples of 
these chemotherapeutics are gemcitabine (Gemca) (Cerqueira et al., 2007), hydroxyurea 
(HU) (Timson, 1975) and camptothecin (CPT) (Wu et al., 1971).  
New methods, such as double labelling with thymidine analogues (Manders et al., 1992) 
and DNA fibre analysis (Jackson and Pombo, 1998; Tuduri, Tourrière and Pasero , 2010), 
have allowed fork restart to be observed on a single molecule basis and this has alluded to 
an active restart pathway at stalled forks. 
After the removal of replication inhibitors, replication forks can restart if the fork is not 
inactivated or a DSB has not formed, although replication can resume once the DSB is 
repaired. For the replisome to remain stalled it is likely that there are structural that increase 
stability after the unwinding of the parental DNA, and lead to replication restart (Petermann 
Helleday, 2010). These structures allow restart through different methods. 
The first possible structure involves the annealing of ssDNA and fork regression creating a 
Holliday junction (HJ) in a chicken foot structure. The annealed daughter ssDNA would 
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need to be degraded and the HJ resolved before replication can restart. Mre11 has been 
suggested as the endonuclease that resects DNA at stalled forks. The second structure is 
displacement loop (D-loop) formation which occurs when strands invade the parental DNA 
and anneal to make a loop that forms two HJs as the replication resumes. This allows 
replication to restart without sister chromatid exchange when the two HJs are resolved. The 
third structure is restarted using a DSB on the replicated DNA that allows strand invasion 
of the replicating strand onto the other parental strand forming a D-loop and a single HJ. 
This can lead to sister chromatid exchange when the single Holliday junction is resolved 
(Petermann Helleday, 2010).  
There are several proteins that have been associated with fork restart; FANCJ/BRIP1 (Wu 
et al., 2008), FANCM (Gari et al., 2008; Yan et al., 2010), WRN (Franchitto et al., 2008; 
Sidorova et al., 2008) and BLM (Davies et al., 2007) are all helicases that have the ability 
to aid the resolution of stalled fork structures and remove obstacles. Other homologous 
recombination (HR) proteins that have been associated with replication fork restart are 
PARP1 (Poly {ADP-ribose} polymerase 1), Mre11, BRCA2 and Rad51. PARP1 promotes 
fork restart by interacting and promoting Mre11 recruitment (Bryant et al., 2009; Haince et 
al., 2008). Mre11 has been shown to promote fork restart through its resection function and, 
in yeast, facilitating the cohesion of sister chromatids (Tittel-Elmer et al., 2009). BRCA2 
promotes fork restart by regulating Rad51 filaments loading onto ssDNA, thus preventing 
excessive resection by Mre11 (Hashimoto et al., 2010; Schlacher et al., 2011). Rad51 is 
also needed for fork restart because it is needed for D-loop formation (Petermann et al., 
2010).  
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Formation of HJs and D-loops requires HR proteins. It has been shown that the lack of 
functional HR proteins, such as Mre11 (Costanzo et al., 2001; Yamaguchi-Iwai et al., 
1999), RAD51 (Sonoda et al., 1998), BRCA2 (Lomonosov et al., 2003), FANCD2 and 
FANCA (Sobeck et al., 2006), can cause a higher level of damage in replication inhibitor 
treated cells, compared with cells with functional HR proteins. This could equate to HR 
proteins being important in the stabilization of replication forks that have stalled and the 
resolution of stalled fork structures (Daboussi et al., 2008; Schlacher et al., 2011).  
Double-strand break response 
The Ku70/Ku80 heterodimer and the MRN complex appear to be recruited first to DNA 
DSB. The MRN complex causes the activation of ATM (Uziel et al., 2003) which 
phosphorylates H2AX histones (γH2AX) (Burma et al., 2001). γH2AX is bound by MDC1 
(mediator of damage checkpoint 1) (Stucki et al., 2005) which associates with Nbs1 in the 
MRN complex (Chapman and Jackson, 2008). Nbs1 interacts with CtIP (Williams et al., 
2009) and BRCA1-BARD1 in the BRCA1-C complex (Yu and Baer, 2000). 53BP1 is also 
recruited to DSBs, but by the methylation of histones (H4-K20) (Botuyan et al., 2006). 
The first process of HR that occurs at DSBs is resection. This will only occur if Ku70 Ku80 
heterodimer has been removed from the DSB DNA ends by VCP (Mimitou and Symington, 
2010; Postow et al., 2008). Resection is performed by Mre11 (Taylor et al., 2010), from the 
MRN complex, and CtIP, from the BRCA1-C complex (Buis et al., 2012). Mre11 nuclease 
activity resects the 5’ strand by a few bases (Taylor et al., 2010). CtIP alongside Mre11 
fully resects the DSB by 50-100nt bases, to create a 3’ overhang (Buis et al., 2012). This 
process is inhibited by 53BP1 which competes with BRCA1-C complex, to favour non-
homologous end-joining (NHEJ) repair of the DSB (Bunting et al., 2010). The BRCA1-C 
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complex is cell cycle dependent and allows HR only in late S or G2 phase, where there is a 
sister chromatid to use as a template for repair synthesis (Chen et al., 2008).  
MDC1 recruits RNF8 to sites of damage where it monoubiquitinates the surrounding H2A-
type histones (Huen et al., 2007; Mailand et al., 2007). This causes chromatin 
rearrangement that allows DSB repair proteins to access the DNA which is essential for 
both NHEJ and HR (Mailand et al., 2007). Polyubiquitination (K48 chains) is essential for 
formation of 53BP1 foci, so the action of the VCP complex and K48 chains may play a role 
in 53BP1 recruitment (Acs et al., 2011). 53BP1, once recruited, acts to amplify the ATM 
signal (Bunting et al., 2010). This leads to the phosphorylation of Kap1, which allows 
chromatin rearrangements needed for both DSB repair pathways (Bencokova et al., 2009; 
White et al., 2012).  
RNF8 can create both K63 and K48 chains, but RNF168 can only produce K63 chains. 
Polyubiquitination (K63 chains) recruits RAP80 in complex with Abraxas and BRCA1 
(BRCA1-A complex) (Wang et al., 2007). Abraxas is a protein with a coiled coil structure 
that is thought to be the core protein on which the BRCA1-A complex assembles (Wang et 
al., 2007). Other proteins in the BRCA1-A complex are BRCC36 (Dong et al., 2003), 
Cdc98 (Liu et al., 2007), BRE (Dong et al., 2003) and MERIT40 (Feng et al., 2009). The 
BRCA1-A complex, excluding BRCA1 is found at stable levels in the cell throughout the 
cell cycle but BRCA1 is found in very low levels in G1 and rises in S and G2 phases (Chen 
et al., 1996).  
BRCC36, a DUB, removes the K63-linked chains from histones after the BRCA1-A 
complex is recruited and promotes the interaction between BRCA1 and BARD1 (Shao et 
al., 2009). It is possible that BRCC36 removes the K63 chains to promote BRCA1 to create 
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K6 chains, of which the function remains unclear (Morris and Solomon, 2004; Wu-Baer et 
al., 2003).  
Rad51 is recruited to DSBs in a RNF8 dependent manner but it is not dependent on the 
creation of K63 chains made by RNF168. This may be because Rad51 is recruited by 
RNF8’s ability to create K48-linked chains (Mailand et al., 2007).  
When resection is complete a human helicase (yeast homologue to Sgs1) unwinds the DNA 
to elongate the 3’ ssDNA end which is bound by RPA (Cejka et al., 2010). Rad51 replaces 
RPA on ssDNA (Wang and Haber, 2004) with the help of BRCA2 (Wong et al., 2003) and 
DSS1 (Gudmundsdottir et al., 2004). It is the interaction between BRCA2 and BRCA1, via 
PALB2, that recruits DSS1, from the proteasome, and BRCA2 to the DSB (Zhang et al., 
2009).  The Rad51 filaments stretches the ssDNA to the homologous sequence on the sister 
chromatid, creating a D-loop (Sung and Robberson, 1995; Yu et al., 2001). Synthesis using 
the sister chromatid as template can then occur as Rad51 dissociates from the ssDNA. The 
end of the newly synthesised DNA is then joined at the other side of the resected area to 
form a HJ. HJs can be resolved by resolvase enzymes, such as Mus81/Mms4 (Hanada et al., 
2007), leading to sister chromatid crossover events depending on which plane the HJ is 
resolved (Schwartz et al., 2012).  
Checkpoint response to replication fork stalling 
When DNA replication becomes stalled, the cell needs more time to finish DNA replication 
and repair before moving into mitosis. Cell cycle checkpoints that help to control this 
progression. The two main checkpoints that control this are the intra-S and S/M phase 
checkpoints.  
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The intra-S phase checkpoint stops late origin firing in favour for the stability of stalled 
forks and synthesis restart. The S/M checkpoint is enforced to stop cells with unreplicated 
or damaged DNA going into mitosis, and leading to chromosomal aberrations.  
When replication forks become stalled they continue to unwind creating excessive ssDNA 
which is coated with RPA (Byun et al., 2005; Longhese et al., 1996; Zou and Elledge, 
2003). RPA presence activates ATR, a checkpoint kinase, and ATRIP. The ATRIP and 
ATR complex localises onto DNA as does Rad17 (Choi et al., 2010). Rad17 binds to 
subunits of RFC and loads the PCNA-like complex, such as 9-1-1, onto the stalled 
replication fork (Zou et al., 2002; Zou et al., 2003). Once loaded the PCNA-like structure 
enables ATR to phosphorylate Chk1, which is a PCNA-like chromatin-bound substrate 
(Kobayashi et al., 2004). 
Activated ATR leads to a multitude of protein pathways being activated, such as DNA 
repair, apoptosis and further checkpoint signalling. ATR specifically phosphorylates Chk1, 
when promoted by other factors such as Claspin (Kumagai and Dunphy, 2000), TopBP1 
(Kim et al., December 15, 2005), Rad9, Rad17 (Zou et al., 2002), TIM and TIPIN 
(Yoshizawa-Sugata and Masai, 2007). This activates Chk1 which phosphorylates CDC25 
A-C (Sanchez et al., 1997), inhibiting cyclin E/A-CDK2 and cyclin B-CDK2 activation. 
Inhibition of CDK prevents loading of the helicase and replisome via Cdc45 (Aparicio et 
al., 1999). This process leads to an elongation of S phase. Without ATR activity, cells lose 
the S/M checkpoint which leads to an accumulation of DSBs.  
Fork progression is also influenced by the presence of various factors mentioned above. For 
example defects in TIM (Ünsal-Kaçmaz et al., 2007), Claspin (Osborn and Elledge, 2003), 
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or TopBP1 slow fork replication rates. TopBP1 slows replication forks by 40% in Xenopus 
egg extracts (Van Hatten et al., 2002). 
Checkpoint response to double-strand breaks 
Stalled forks can collapse into DSBs, and this activates the S/M checkpoint until they are 
completely repaired. As discussed above, stalled forks lead to ssDNA which activates the 
ATR pathways and consequently the intra-S phase checkpoint, to lengthen the time the cell 
is in S-phase. When a DSB is sensed the ATM pathway is stimulated alongside the ATR 
pathways.  
MDC1, which is one of the earliest proteins involved in DSB response, is known to 
associate with Chk2 in the ATM/Chk2 cell cycle checkpoint pathway (Lou et al., 2003b). 
MDC1 is essential for the recruitment of BRCA1, as without MDC1, BRCA1 does not 
relocalize and is not hyperphosphorylated (Lou et al., 2003a). This affects the function of 
BRCA1 and its ability to bind in its several complexes that are needed for DSB repair. 
BRCA1 is also needed for the phosphorylation of Chk1 following DNA damage (Lou et al., 
2003a) which suggests BRCA1 may aid the regulation of the G2/M checkpoint through 
Chk1 (Yarden et al., 2002). Mre11 has also been shown to further activate the Chk2 which 
targets the ATR/Chk1 pathway through CDKs and p53 (Lee and Paull, 2004).  
It is the activation of Chk1 and Chk2 that, through down-regulation of CDK activity, 
control the regulation from S-phase through G2 and into mitosis.  
Gemcitabine 
Gemcitabine is one of several drugs whose target is to cause faulty DNA replication and 
create DNA damage that will kill the cancer cells. Gemcitabine, 2’,2’-difluoro-2’-
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deoxycytidine (dFdC) (Bianchi et al., 1994) is similar to the DNA building block 
deoxycytidine, but it has two fluorine atoms replacing hydrogen on its 2
nd
 carbon in its 
ribose ring (Hertel et al., 1990). 
Gemcitabine is metabolised into two compounds; 5’-diphosphate (dFdCDP) and 5’-
triphosphate (dFdCTP) (Cerqueira, Fernandes and Ramos, 2007). dFdCDP has been shown 
to inhibit ribonucleotide reductase (RNR) by disrupting the kinetics of both of the RNR two 
protein subunits (R1, R2). RNR catalyzes, dependent on its two active subunits, the 
reaction that produces deoxyribonucleotides that are the building blocks of DNA. Therefore 
there is a reduction in dNTPs for DNA synthesis in Gemcitabine treated cells. dFdCTP is 
similar enough to deoxycytidine 5-triphosphate (dCTP) that they compete for incorporation 
during DNA synthesis. Once dFdCTP is added onto a synthesising strand, it is only 
possible to add a single deoxyribonucleotide before the synthesis is inhibited (Cerqueira et 
al., 2007).  
Gemcitabine therefore acts in three ways using its two metabolites; firstly, dFdCDP reduces 
the amount of free dNTPs for DNA synthesis by inhibiting RNR: secondly, Gemcitabine 
metabolism increases due to the lack of dNTPs: finally, dFdCTP is incorporated into the 
DNA which stops further DNA being synthesised (Cerqueira et al., 2007).  
Gemcitabine is a FDA and EMEA approved drug treatment for non-small cell lung cancer 
(Shepherd et al., 1997), pancreatic adenocarcinoma (Plate et al., 2005), breast cancer, 
ovarian cancer and bladder cancer (Nawrocki et al., 2002). It has been trialled alongside 
Carboplatin, Cisplatin or Imatinib in pancreatic cancer and in combination with Cisplatin in 
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breast and non-small cell lung cancer (Cerqueira, Fernandes and Ramos, 2007; Nagourney 
et al., 2008) . 
BRCA1 in breast cancer 
BRCA1 (Breast cancer type 1 susceptibility protein), previously mentioned to be important 
in DSB repair, is a tumour suppressor found on chromosome 17q21 in humans that, when 
mutated, causes breast cancer. It was isolated through linkage analysis of families with high 
incidence of early onset breast and ovarian cancer (Hall et al., 1990). An inherited mutation 
in BRCA1 is recessive; therefore for tumour development a loss of heterozygosity is 
needed. Inherited breast cancer is estimated to be causative of 5-10% of breast cancer cases, 
but inheriting a mutation gives the individual a 40-80% risk of developing breast cancer 
(Wang et al., 2012). There are a multitude of inherited BRCA1 mutations that can be traced 
through populations such as among Ashkenazi Jews. Most of the mutations found in 
BRCA1 are protein-truncating mutations and they mostly are in the two most functional 
domains in BRCA1 (Wang et al., 2012).  
The two domains are the N-terminal Zinc RING finger domain and the C-terminal double 
BRCT domain. The RING domain provides BRCA1 with its E3 ubiquitin ligase activity 
and interacts with BARD1 (Xia et al., 2003). The BRCT domain binds to many proteins, 
such as CtIP, p53 and BRCA2 (Drikos et al., 2009).  
BRCA1 is involved in many important cellular functions, such a cell cycle checkpoint 
control and DSB repair. In the DSB repair, as previously discussed, BRCA1 is involved in 
promoting HR through competing with 53BP1, as well as regulating Mre11 and CtIP end 
resection, BRCA2 recruitment to DSBs, S and G2/M checkpoint control during DNA 
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replication. Defects in BRCA1 risk genomic integrity through faulty DNA replication, 
DNA repair and cell cycle progression. This would lead to chromosomal rearrangements, 
duplication and deletions of genetic material to daughter cells and eventually to cell death. 
 
Aims of project 
Gemcitabine causes fork stalling through its inhibition of RNR and incorporation into the 
newly synthesized DNA strand. Gemcitabine is currently used to treat cancer because it 
causes DNA replication to slow and induces DSBs at stalled forks, leading the cells to cell 
death. It is used in ovarian and breast cancer treatment alongside other drugs such as 
Cisplatin. Therefore, we decided to measure the response of the HR-defective BRCA1-
deficient breast cancer cell line HCC1937.  
 
Our main questions were:- 
- Does BRCA1 status affect fork stalling or restart after Gemcitabine treatment? 
- Does BRCA1 status affect the survival of cells after Gemcitabine treatment? 
- What are the localization foci timings of 53BP1 and Rad51 in BRCA1-defective 
cells after Gemcitabine treatment? 
- Does BRCA1 status affect the induction of p-RPA32 after Gemcitabine treatment? 
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METHODS 
Unless otherwise stated chemicals were obtained from Sigma-Aldridge (St Louis, MO, 
USA) or Thermo Fisher Scientific (Loughborough, UK) 
Unless otherwise stated tissue culture supplies were obtained from Corning (Corning, NY, 
USA) 
Materials 
Primary Antibodies 
Mouse α-BrdU (Beckton Dickinson, Oxford, UK) 
Mouse α-ɣH2AX (Millipore, Billerica, MA, USA) 
Mouse α-Tubulin 
Rabbit α-53BP1 (Bethyl Laboratories, Montgomery, TX, USA) 
Rabbit α-RPA32-P (Bethyl Laboratories, Montgomery, TX, USA) 
Rat α-BrDU (AbD Serotec, Dusseldorf, Germany) 
Secondary Antibodies 
α-Mouse AlexaFluor 488 (Invitrogen, Grand Island, NY, USA) 
α-Mouse HRP (Dako, Glostrup, Denmark) 
α-Rabbit AlexaFluor 555 (Invitrogen, Grand Island, NY, USA) 
α-Rabbit HRP (Dako, Glostrup, Denmark) 
α-Rat AlexaFluor 555 (Invitrogen, Grand Island, NY, USA) 
siRNAs 
ON-TARGETplus SMARTpool, Human BRCA1 siRNA (672) [L-003461-00-0010] 
(Thermo Fisher Scientific, Loughborough, UK) 
ON-TARGETplus Non-targeting siRNA#1 [D-001810-01-20] (Thermo Fisher Scientific, 
Loughborough, UK) 
Cell Lines 
U20S osteosarcoma (Niforou et al., 2008) 
HCC1937 with empty pcDNA3 vector (BRCA1-ve cells) (Scully et al., 1999) 
HCC1937 with pcDNA3BRCA1 vector (BRCA1+ve cells) (Scully et al., 1999) 
Solutions 
Spreading buffer 
200mM Tris-HCl pH 7.4 
50mM EDTA 
0.5% SDS 
HCl solution 
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5.2ml 37% Hydrochloric Acid 
19.8ml H2O 
Blocking solution 
200µl Tween20 
2g Bovine Serum Albinum 
200ml PBS 
UTB buffer 
50mM Tris pH7.5 
150mM β-mercaptoethanol 
8M Urea 
PI/RNase solution (per sample) 
9µl Propidium Iodide (PI) 
0.3µl RNase A 
490.7µl PBS 
TBSTx10 
12.1g Tris 
81.8g NaCl 
Correct pH to 7.9 with HCl 
Make up to 1litre with dH20 
Ponceau stain  
1g Ponceau S 
50ml acetic acid 
Make up to 1L with ddH2O 
0.2% Methylene Blue Stock Solution 
0.2g methylene blue-trihydrate 
100ml dH2O 
0.025% Methylene Blue Staining Solution 
62.5ml of 0.2% Methylene Blue stock solution 
437.5ml dH2O 
Protocols 
Tissue Culture 
Cells were maintained in Gibco
®
 by Life Technologies, Iscove’s Modified Dulbecco’s 
Medium with added L-Glutamine and 25mM HEPES. Grown with 15% FCS and 
Penicillin/Streptomycin and grown at 37°C, 5% CO₂. Routine passages were done 
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regularly depending on cell confluence. When cells reached 90% confluence they were 
passaged at a 1:3 dilution.  
Clonogenics/Cell survival assay 
Cells were seeded in 6 well plates at two total cell numbers for each drug concentration and 
left overnight to adhere. The following day cells were treated for 2hrs with the desired 
Gemcitabine concentration. The cells were washed twice with warm PBS and released into 
fresh media. The cells were checked regularly to see if the surviving colonies had reached 
~30 cells. When the majority of colonies reached this size, they were fixed and stained with 
0.025% Methylene Blue solution. The media was taken off the cells and they were washed 
twice with PBS. Methylene blue was added to the well to fix and stain the cells for 10 
minutes. This was washed off and the plates are left to dry before the colonies in each 
condition, were counted.  
Fibre assay using CldU/IdU labelling 
1) Labelling. Cells were seeded overnight in 6 well plates. CldU was added to cells at 
a final concentration of 25µM and incubated for 20 minutes. IdU was added to the 
cells at a final concentration of 250µM and incubated for 20 minutes. The cells were 
washed with ice cold PBS and trypsinised and collected in PBS. Cells were diluted 
to a concentration of 5x10
5
/ml in PBS. Cells that were treated with Gemcitabine 
followed a different labelling protocol. CldU (25µM) was added to cells for 20 
minutes and Gemcitabine was added, at the desired concentration, and incubated for 
30 minutes, still in CldU. IdU (250µM) was then added for either 2 or 4 hours and 
cells were harvested with PBS as described before.  
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2) Spreading. 2µl of a sample was pipeted onto a microscope slide and left to dry for 
5-7 minutes or until the sample was ‘sticky’ but not dry. 7µl of spreading buffer was 
added and stirred into the sample, to lyse the cells and degrade protein structures, 
and incubated at RT for 2 minutes. The slides were tilted so the sample runs down 
the slide slowly, taking around 3-5 minutes to get to the bottom edge of the slide. 
The slides were air dried before being fixed in Methanol/Acetic Acid (3:1) for 10 
minutes. These were air dried and stored in the fridge. 
3) Immunostaining. Slides were washed twice with water for 5 minutes to rehydrate 
the slides. The slides were rinsed with HCl solution and incubated in HCl solution 
for 80 minutes. The slides were rinsed twice with PBS and washed twice with 
blocking solution (5-10 minutes each) before incubating at RT in blocking solution 
for 30-60 minutes. 115µl of primary antibody mix was added to the slides, covered 
with a large coverslip and incubated for 1hr. Primary antibody solution contained 
Rat αBrDU (1:1000) and Mouse αBrdU (1:500) in blocking solution. Slides were 
rinsed three times with PBS and fixed with 4% paraformaldehyde/PBS for 10 
minutes. Slides were rinsed three times with PBS and washed three times with 
blocking solution. 115µl of secondary antibody mix was added to the slides, 
covered with a large coverslip and incubated for 2hrs. Secondary antibody solution 
contained αRat AlexaFluor 555 and αMouse AlexaFluor 488 (both 1:500) in 
blocking solution. Slides were rinsed twice with PBS, washed three times with 
blocking solution and washed twice with PBS. Slides were mounted with mounting 
medium and a large coverslip and stored at -20
o
C.  
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Fibres were either counted for structure type or fibre length was counted by pixels using 
ImageJ software. This was achieved by imaging a scale bar on a microscope slide and using 
this image to identify a conversion factor from µMs to pixels to kilobase pairs of DNA. 
Foci protocol 
Cells were plated overnight on coverslips in a six well plate. Media was removed and cells 
were fixed for 10 minutes in 4% paraformaldehyde/PBS. Cells were washed in PBS and 
stored in PBS in the fridge. Cells were permeablised with 0.25% Triton X100/ PBS 
solution at RT for 5 minutes before being washed twice with PBS and washed three times 
with blocking solution. 80µl of Mouse α-ɣH2AX antibody (1:1000) was added to the 
coverslip and incubated for 1hr at RT. Cells were washed twice with PBS and washed three 
times with blocking solution. 80µl of α-mouse 488 antibody (1:500) was added to the 
coverslip and incubated in the dark for 2hrs at RT. Cells were washed twice with PBS and 
washed three times with blocking solution. 80µl of Rabbit α-53BP1 antibody (1:3000) was 
added to the coverslip and incubated for overnight at 4
o
C. Cells were washed twice with 
PBS and washed three times with blocking solution. 80µl of α-rabbit 555 antibody (1:500) 
was added to the coverslip and incubated in the dark for 2hrs at RT. Cells were washed 
twice with PBS and mounted with Mounting Medium containing DAPI stain onto 
microscope slides and stored at 4
o
C.  
ɣH2AX staining was quantified using the overall signal of green in RGB photo using 
ImageJ. This was normalised by comparing the quantified green signal of the same cells 
imaged for DAPI stain.  
FACS protocol 
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Cells were grown in a T25 flask until confluent under normal tissue culture conditions. 
Cells were treated to create the following conditions:- 
- CPT- Camptothecin at 1µM for 1hr with 50µM of Mirin (Tocris Bioscience, Bristol, UK) 
throughout or with 10µl of DMSO throughout. 
- Gemcitabine- Gemcitabine at 6µM for 2hr with 50µM of Mirin throughout or with 10µl 
of DMSO throughout. 
Cells were released into fresh media and harvested either immediately (CPT), or after 2 or 
48 hours (Gemcitabine). To harvest the cells, they were trypinised (Invitrogen, Grand 
Island, NY, USA) and resuspended in 1ml ice cold PBS before centrifuging at 5,000rpm for 
5 minutes. The cells were resuspended in ice cold 70% EtOH and vortexed. They were then 
stored at 4
o
C until they were washed before being PI stained.  
Cells were centrifuged at 2,500rpm for 4 minutes at 4
o
C and the supernatant was gradually 
removed. Cells were washed with PBS and centrifuged again. Cells were resuspended in 
PBS for 1hr at RT before being centrifuged again. Finally, cells were resuspended in 500µl 
of PI/RNase solution and incubated for at least 1hr at 4
o
C in FACs tubes. Samples were 
stored for up to 7 days.  
Western Blotting 
Samples were plated overnight and treated with various drugs for the correct conditions. 
Harvested cells were counted and resuspended in UTB buffer to the concentration of 
~5x10
6
cells/ml and kept on ice. Samples were sonicated twice for 10 seconds at 4.5 input 
power and cooled with ice before centrifuged at full speed for 10 minutes at 4
o
C. The 
supernatant was transferred to a new tube and loading buffer was added at a ratio of 1:4. 
Samples and protein marker (New England BioLabs, Hitchin, UK) were boiled before 20µl 
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of sample was loaded into a 12% acrylamide gel. The gel was then run for 80 minutes at 
150V before being transferred onto transfer membrane for 90 minutes at 100V. The transfer 
membranes (GE Healthcare UK, Little Chalfont, UK) were stained with ponceau stain and 
cut at 46kDa, 27kDa and 5kDA. Membranes were then blocked in 5% Milk/TBST for 1hr 
at RT, before being separated and put into the first antibody and incubated overnight at 4
o
C. 
The first antibodies were Mouse α-Tubulin (1:2000), Rabbit α-RPA32-P (1:500) and 
Mouse α-ɣH2AX (1:1000). Membranes were washed three times in TBST for 5 minutes 
before being blocked in 5% Milk/TBST for 20 minutes at RT. Membranes were placed into 
the corresponding secondary antibody and incubated at RT for 90 minutes. Secondary 
antibodies were α-Mouse and α-Rabbit, both conjugated to HRP and both at 1:5000 
concentration. The membranes were washed three times in TBST for 5 minutes and added 
to an ECL wash (Thermo Fisher Scientific, Loughborough, UK) and developed.  
 Separating Gel (12%) 20ml Stacking Gel (5%) 10ml 
Water 6.6ml 6ml 
1.5M Tris pH 8.8 5ml - 
1M Tris pH 6.7 - 2.5ml 
Acrylamide (30%) 8ml 1.34ml 
SDS (10%) 200µl 100µl 
APS 200µl 100µl 
TEMED 18µl 10µl 
Table 1- Recipes of acrylamide gels used for western blotting. 
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siRNA transfection protocol 
Tube1: diluted siRNA (µl/well) Tube2: diluted DharmaFECT (µl/well) 
20µM of siRNA = 4µl DharmaFECT 1 reagent = 4µl 
OptiMem medium = 196µl OptiMem medium = 196µl 
Table 2- Recipe of siRNA transfection reagents  
Volumes above based on single wells of a 6-well plate. 
Seed cells 12hours before transfecting. Ingredients are added with desired siRNA into tube 
1 and 2 and incubated for 5 minutes at RT. Tube 1 and Tube 2 are then added to each other 
slowly and incubated for 20 minutes at RT. The final solution is then added to each well in 
the 6-well plate to make up the medium (antibiotic-free) to 2ml. Media is changed ~16 
hours after transfection. siRNA is considered to work ~48-72 hours after transfection.  
DharmaFECT 1 was purchased from Thermo Fisher Scientific (Loughborough, UK) and 
OptimMEM was purchased from Invitrogen (Grand Island, NY, USA). 
  
82 | P a g e  
 
RESULTS 
Fork stalling and BRCA1 status 
The DNA fibre technique uses 
double labelling with thymidine 
analogues (CldU and IdU) to assess 
the level of DNA replication fork stalling in the presence of inhibitors of DNA replication. 
HCC1937 BRCA1-proficient and -deficient cells were labelled to investigate the influence 
of BRCA1 status on Gemcitabine-induced fork stalling. 20 minutes into the 1
st
 label (CldU, 
50 minutes total), a dose of 2µM Gemcitabine was added and remained present throughout 
the 2
nd
 label (IdU, two or four hours) (Figure 1). Control cells were untreated and both 
labels were added for 20 minutes consecutively. Images of the fibres were analysed for 
replicative structures (Figure 3) defined by the two labels (Figure 2). The experiment was 
repeated with a 6µM dose of 
Gemcitabine (Figure 4 & 5) as 
HCC1937 cells showed some 
resistance to the replication 
inhibitory effects at the lower 
concentration. The percentage of CldU-only labelled tracks, a measure of stalled forks, 
increased in the 2µM Gemcitabine treated cells compared with control, and the increase 
was greater in the 4 hour IdU treatment (Figure 3). After Gemcitabine treatment, the 
BRCA1-deficient cells showed a higher level of fork stalling compared to control than the 
BRCA1-proficient cells. In the 6µM Gemcitabine experiment a similar result was seen 
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(Figure 5). The overall increase shows the DNA replication fork stalling by Gemcitabine 
occurs in HCC1937 cells. BRCA1-deficient cells have a lower rate of fork stalling in the 
absence of Gemcitabine (Supplementary Figure 1). The increased level of fork stalling seen 
in the BRCA1-deficient Gemcitabine treated cells suggests that BRCA1 may be involved in 
fork progression in the presence of Gemcitabine. This can been seen in the images of the 
fibres (Figure 4). The increase in CldU-only tracks seen in the 4 hour IdU treatment 
compared to the 2 hour IdU treatment is indicative of nucleotide degradation of the second 
label (see Discussion). 
 
Using the same DNA fibre experimental images, the length (in pixels) of the labels for each 
fibre were measured and converted into μM and kilobase pairs (kb) to quantify the rate of 
DNA replication with and without Gemcitabine treatment in both BRCA1 cell types. The 
rate of fork speed in the 1
st
 label (CldU) was decreased with Gemcitabine treatment in both 
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cell types, but BRCA1-deficient cells showed a greater decrease in replication rate compare 
to BRCA1-proficient cells (Figure 6a). The rate of fork speed in the 2
nd
 label (IdU) was 
decreased to less than 10% of the untreated control IdU fork speed after 2hrs IdU labelling 
and to below 4% after 4hr IdU labelling (Figure 6b). The BRCA1-deficient cells showed a 
greater decrease in fork speed in the 2hr IdU labelling in compared to BRCA1-proficient 
cells, but this difference was not as great in the 4hr IdU labelling. These results show that 
BRCA1-deficient cells show a greater sensitivity to Gemcitabine treatment in both 1
st
 and 
2
nd
 label fork speed rates, than BRCA1-proficient cells.   
 
When looking at the kilobases of replicated DNA throughout the time course (Figure 7) we 
can see that BRCA1-proficient cells slow the amount of DNA replicated 20 minutes after 
addition of Gemcitabine and appear to stall replication completely around 150 minutes. 
BRCA1-deficient cells appear to slow replication at 20 minutes although more DNA 
appears to have been replicated, and also stall replication forks completely by 150 minutes. 
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The reduction of the total 
amount of DNA replicated in 
BRCA1-deficient cells early 
during Gemcitabine 
treatment, may be indicative 
of DNA degradation. The 
final length of replicated 
DNA in the BRCA1-
proficient cells is slightly 
shorter than at the previous time point (150 minutes), which may also be indicative of DNA 
degradation of stalled forks. The greater difference in BRCA1-proficient and –deficient 
total amount of replicated DNA before fork stalling suggests that BRCA1-deficient cells 
have a higher speed of replication than BRCA1-proficient cells.  
The DNA fibre experiment was repeated in BRCA1 siRNA (BRCA1-ve) or non-targeted 
control (NTC) siRNA (BRCA1+ve) U2OS cells with the same labelling protocol and 
treatment with 2µM Gemcitabine (Treated, T) or untreated (Control, C) (Supplementary 
Figure 2). The treatment followed the time course and labelling in the previous experiment, 
(Figure 1) but without the 4hr IdU treatment. Spread fibres were stained using the same 
protocol as before and analysed for DNA replication structures. Both Gemcitabine-treated 
cell lines showed increased levels of fork stalling compared to the untreated control (Figure 
8) and slightly more fork stalling in the BRCA1 siRNA-treated cells, than the NTC siRNA-
treated cells. This suggests Gemcitabine does stall forks effectively in U2OS cells and the 
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increase in fork stalling in the BRCA1-deficient cells also occurs in a BRCA1 siRNA 
knockdown and therefore it supports the idea of BRCA1 status affecting fork stalling.  
 
Fork restart and BRCA1 status 
The DNA fibre experiment can also be used to assess the level of fork restart after fork 
stalling induced by inhibitors of DNA replication. A dose of 2µM Gemcitabine was used to 
treat HCC1937 BRCA1-proficient and -deficient cells from 20 minutes into the 1
st
 label 
(140 minutes total), and the Gemcitabine is washed out before adding the 2
nd
 label (two 
hours) (Figure 9). Control cells were untreated and both labels were added for 20 minutes 
consecutively. DNA fibre 
images were analysed for 
replicative structures defined 
by the two labels (Figure 10 & 
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Supplementary Figure 3). The fibres show levels of replication fork stalling similar to 
during Gemcitabine treatment and a slight increase in fork stalling in BRCA1-deficient 
cells as shown in the DNA fibres fork stalling experiment. Fork stalling persists for two 
hours after release from Gemcitabine suggesting the DNA replication inhibition is 
prolonged after Gemcitabine is removed. This suggests BRCA1 has no role in fork restart 
of Gemcitabine stalled forks. 
 
BRCA1 status effects on 53BP1 and ɣH2AX immunofluorescent staining 
DNA damage from Gemcitabine treatment was measured using 53BP1 and ɣH2AX foci. 
53BP1 foci indicate the presence of, specifically, DSBs and ɣH2AX is present at sites of 
DNA damage including stalled forks and DSBs. 
HCC1937 BRCA1-proficient and –deficient cells were treated with Gemcitabine (2 or 
6µM) or DMSO for two hours and released into fresh media for several time periods to 
allow DSBs to be induced and DNA repair response mechanisms to occur. Cells were 
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fixed, permeabilized and immunofluorescence stained for the presence of 53BP1 and 
ɣH2AX.  
 
In the 2µM Gemcitabine foci experiment, there were more cells that had 53BP1 foci 
(Figure 11a) and more foci in each 53BP1 positive cell (Figure 11b) after release from 
treatment (24 & 48 hours) in the BRCA1-deficient cells compared to BRCA1-proficient 
cells. However, there was little or no increase in the number of 53BP1 foci compared to the  
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control (DMSO), 
suggesting that the 2µM 
Gemcitabine treatment did 
not induce many DSBs in 
HCC1937 cells. When the 
dose of Gemcitabine was 
increased to 6µM, the 
number of 53BP1 foci per 
positive cell increased 
dramatically over time, 
suggesting that DSBs were 
induced by the treatment 
(Figure 12b & 13). The 
difference between the 
percentages of BRCA1-
deficient 53BP1-positive 
cells compared to BRCA1-
proficient 53BP1-positive 
cells was similar after 6µM 
Gemcitabine treatment as 
it was in the 2µM 
Gemcitabine treatment 
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(Figure 12a & 13). A decrease in the 53BP1 positive cells, at late time points, was seen in 
in both experiments, possibly because of high cell death due to the amount of damage 
(Figure 14). The number of 53BP1 foci increased in the BRCA1-proficient cell line until 72 
hours, but in the BRCA1-deficient cell line the number of foci increased more strongly 
until it peaked at 48 hours (Figure 12b). The reduction in foci in the BRCA1-deficient cells 
at 72 hours may be due to high levels of cell death (Figure 14).  
 
In the 2µM Gemcitabine foci experiment, the levels of ɣH2AX staining did increase but 
were not consistent (Figure 15a & b). These cells were measured for their ɣH2AX staining 
in two ways: firstly, the level of staining was measured by the concentration of green 
fluorescence in ImageJ (http://rsbweb.nih.gov/ij/) (Figure 15a); and secondly, by counting 
the number of cells positive for ɣH2AX staining (Figure 15b). This was attempted because 
the base level of ɣH2AX staining was high and counting positive cells did not account for 
the changes in staining intensity. Both methods showed similar results and are 
interchangeable. The 6µM Gemcitabine foci experiment had two controls; DMSO, which 
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was fixed immediately 
after release, and C24, 
which was treated 
with DMSO and fixed 
after 24 hours release 
(Figure 16). C24 was 
used to show the 
background level of 
ɣH2AX staining was 
consistent throughout 
the time course, and a feature of the cells, not an effect of seeding the cells. BRCA1-
proficient cells showed an increase in ɣH2AX staining, peaking at 72 hours, similar to the 
53BP1 foci level. The BRCA1-deficient cells showed a peak in ɣH2AX staining at 48 
hours, similar to the 53BP1 foci level (Figure 16 and Figure 14). This suggests the peaks in 
53BP1 foci and presence of ɣH2AX after Gemcitabine treatment correlate. It also suggests, 
as they are both markers for DSBs, that DSBs are induced earlier (48 hours) in BRCA1-
deficient cells than they are in BRCA1-proficient cells (72 hours). This suggests BRCA1 is 
involved in the prevention of DSBs at stalled replication forks. 
Levels of phospho-RPA induced by Gemcitabine treatment and BRCA1 status 
Phospho-RPA covers ssDNA and therefore, can be used to measure of the induction of 
ssDNA at stalled replication forks. HCC1937 BRCA1-proficient and –deficient cells were 
not treated (Control), treated with 6µM Gemcitabine for 2 hours and released for 2 or 48 
hours in the presence of Mirin or DMSO, or treated for 1 hour with 1µM Camptothecin 
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(CPT) in the presence of Mirin or DMSO. Protein samples for Western blot were generated 
using sonication. Membranes were probed for Tubulin, phospho-RPA, and ɣH2AX (Figure 
17).  
Control samples showed a 
slightly higher level of 
phosphorylated RPA in 
BRCA1-deficient samples 
and all samples had a high 
baseline of ɣH2AX that 
agrees with the high level of 
immunofluorescent ɣH2AX 
staining previously 
discussed. The CPT 
treatment was used as a test 
for DNA resection and 
inhibition of resection by 
Mirin, which is an inhibitor 
of Mre11-dependent 
resection (Garner et al., 
2009; Sartori et al., 2007; 
Wall et al., 1966). DMSO 
treatment was used as a 
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control because Mirin was dissolved in DMSO. Cells treated with CPT showed higher 
levels of ɣH2AX after treatment, as expected. Phospho-RPA was equally induced in 
BRCA1-proficient and –deficient cells, suggesting that BRCA1-deficient HCC1937 cells 
are proficient in resection. Phospho-RPA was not decreased by Mirin treatment in BRCA1-
deficient cells, suggesting that ssDNA generation after CPT treatment is Mre11-
independent in absence of BRCA1 (Figure 17c).  
In the 2 hour release (2+2hr) BRCA1-deficient cells have higher levels of phospho-RPA 
than BRCA1-proficient cells. This is decreased in the Mirin treatment, suggesting the 
phospho-RPA is partially caused by Mre11-dependent resection after Gemcitabine has 
stalled DNA replication forks (Figure 17a). After 48 hours release (2+48hr) BRCA1-
deficient cells have much higher levels of phospho-RPA than BRCA1-proficient cells, and 
this is also increased after 2 hours release (Figure 17b). There is no noticeable difference 
between the levels of phospho-RPA between DMSO and Mirin treated cells, in either cell 
line after 48 hours release, suggesting that the phospho-RPA is not Mre11-dependent at 
later time points. We conclude from our 53BP1 and ɣH2AX immunofluorescence data that  
high levels of DSBs have formed in the BRCA1-deficient cell line after 48 hours release, 
which would be supported by the presence of the high level of ɣH2AX in the cells released 
for 48 hours. The high levels of phospho-RPA in BRCA1-deficient cells in both the 2 and 
48 hours release, also suggest that BRCA1-deficient cells have more damaged DNA 
compared to BRCA1-proficient cells, before and after Gemcitabine treatment.  
BRCA1 status and S phase accumulation 
Replication inhibitors cause S phase accumulation because DNA damage and stalled forks 
cause activation of cell cycle checkpoints to stop cells going into G2 phase and mitosis with 
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unreplicated DNA. This is an important control experiment because Gemcitabine DNA 
damage is S-phase dependent. 
Cells were grown and treated with the same treatment combination as for the Western blots 
(without the CPT conditions), fixed, and stained with PI to label the DNA content of the 
cells. The FACS (Fluorescent-activated cell sorting) was set up to process 20,000 events 
and the cells which show the appropriate DNA content for cells in G1, S and G2 phases of 
the cell cycle (Supplementary Figure 4) were analysed. Replication inhibitors cause G1 (or 
early S phase) accumulation. 
 
BRCA1-deficient cells accumulate in S-Phase from 2 hours release after Gemcitabine 
treatment, whereas BRCA1-proficient cells do not accumulate until 48 hours release form 
Gemcitabine (Figure 18). This may be because BRCA1-proficient cells still have a 
functional G2/M checkpoint. There are more BRCA1-deficient cells in S phase in all 
treatments compared to respective treatments in BRCA1-proficient cells. This could be 
indicative of BRCA1-proficient cells accumulating in early S phase later.  
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BRCA1 status and colony survival 
HCC1937 BRCA1-proficient and –deficient cell lines were plated at two different cell 
densities for each treatment concentration and treated with various concentrations of 
Gemcitabine for 2 hours to assess the sensitivity of these cell lines to this treatment. 
Gemcitabine was removed and cells were grown in fresh medium for between 10-28 days. 
The colonies that survived were counted and compared to the plating survival rate of 
untreated cells.  
 
BRCA1-deficient cells have fewer colonies that survive doses of Gemcitabine between 
1µM and 10µM, than BRCA1-proficient cells (Figure 19). This seems to be in contrast to 
the 20µM concentration, but the higher concentration (over 20µM) data are incomplete and 
need to be repeated. This suggests that BRCA1-deficient cells are more sensitive to 
Gemcitabine at concentrations up to 10µM, with the greatest difference at 5µM. This 
suggests BRCA1 status affects cellular sensitivity to Gemcitabine. 
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DISCUSSION 
Here we have shown that BRCA1-proficient cells show less Gemcitabine induced fork 
stalling and slowed replication forks progress faster, which suggests BRCA1 to be involved 
in slowed fork progression leading to the stalling of forks.  The total length of newly 
synthesised DNA decreases during Gemcitabine treatment in BRCA1-deficient cells, which 
may be indicative of DNA degradation. The absence of BRCA1 leads to earlier induction 
of 53BP1 foci and to higher levels of ɣH2AX foci and phospho-RPA after Gemcitabine 
treatment. Finally, BRCA1-deficient cells are slightly more sensitive to Gemcitabine at 
concentrations under 10µM. 
There was increased fork stalling (CldU-only tracks) during Gemcitabine treatment in 
BRCA1-deficient cells, and the percentage of CldU-only tracks increased with longer 
incubations in Gemcitabine and IdU. There was also a decrease in the total length of DNA 
replicated in BRCA1-deficient cells early during Gemcitabine treatment. Both these 
observations may be indicative of DNA degradation during Gemcitabine-induced fork 
stalling. After prolonged Gemcitabine treatment, the final length of replicated DNA in the 
BRCA1-proficient cells was also slightly shorter than at the first time of stalling, which 
may also be indicative of DNA degradation of stalled forks at later time points. The higher 
amount of total replicated DNA in BRCA1–deficient cells before fork stalling suggests that 
BRCA1-deficient cells have a higher speed of replication than BRCA1-proficient cells in 
the absence of Gemcitabine. The dramatic level of DNA degradation in the BRCA1-
deficient cells and the lesser amount in the BRCA1-proficient cells suggests that the 
presence of BRCA1 protects against DNA degradation. 
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This alongside the presence of Mirin-sensitive phospho-RPA after Gemcitabine fork 
stalling in BRCA1-deficient cells, also supports BRCA1 having a role in protecting stalled 
forks but specifically from Mre11 degradation, which is supported by Schlacher, 2012 
(Schlacher et al., 2012). The earlier induction of increased levels of 53BP1, phospho-RPA 
and ɣH2AX at 48 hours in the absence of BRCA1 further suggests BRCA1 is protecting 
Gemcitabine slowed or stalled forks, and this protection delays the collapse into DSBs. The 
increased phospho-RPA levels (with and without Mirin treatment) may also be related to 
the formation of DSBs when BRCA1 is absent. We conclude that there is no change the 
phospho-RPA level after Mirin treatments because in response to DSBs, phospho-RPA 
levels may be generated by mechanisms other than Mre11-dependent resection. 
As the replication fork speed is higher in untreated BRCA1-deficient cells, and the G2/M 
checkpoint is less effective in causing G1 accumulation with functional BRCA1, it may be 
because BRCA1-deficient cells cycle faster and without intact checkpoints that more DNA 
damage accumulates. This could also explain the earlier induction and higher levels of 
53BP1 and ɣH2AX in BRCA1-deficient cells.  
BRCA1-proficient cells are slightly more resistant to Gemcitabine at concentrations under 
10µM. This resistance may be because cells accumulated less DNA damage than BRCA1-
defective cells. Above 10µM concentration, BRCA1-proficent cells are more sensitive to 
Gemcitabine. The molecular explanation behind this is unclear, but it may be because 
BRCA1 presence allows G2/M checkpoint to be active and may thereby protect cells from 
DNA damage-induced apoptosis. 
BRCA1 has been shown to be important in preventing stalled replication forks from 
accumulating DNA damage and it is, therefore, interesting to remember that BRCA1 is also 
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functional in DSB repair. BRCA1’s function in supporting stalled forks is upstream of DSB 
formation and therefore BRCA1 must accumulate before DSB repair response signalling 
that recruits BRCA1. The specific biological function of BRCA1 at stalled replication forks 
is not clear, but from these results, BRCA1 is involved in supporting (perhaps physically) 
the replisome at stalled forks during replication inhibition. Some replisome proteins, such 
as the alternative clamp, clamp loader and the special polymerases, are exchanged at stalled 
forks for progression and it is not unreasonable that proteins are recruited to support the 
fork and replisome during these changes. During the repair of DSBs, the broken and 
resected DNA needs to be protected and supported, and recruited proteins do not all have 
direct roles in repairing the DNA strands but some are for maintaining structure of recruited 
proteins. Therefore, it is not surprising that some of these recruited HR proteins are also 
associated with protecting stalled forks, such as BRCA2 and Rad51 (Lomonosov et al., 
2003; Petermann et al., 2010). BRCA2 and Rad51 are associated with protecting stalled 
forks, in contrast to BRCA1, BRCA2 and Rad51 promote fork stalling during Gemcitabine 
treatment and do not appear to protect Gemcitabine-stalled forks from becoming DSBs 
(RM. Jones, personal communication). 
Some BRCA1-deficient cell lines have been reported to be resection-defective, but the 
observed Mirin-sensitive induction of phospho-RPA after Gemcitabine treatment suggest 
that Mre11-dependent resection is not defective and the effects of absent BRCA1 could 
induce Mre11- and CtIP-dependent resection. The BRCA1-dependent protection of stalled 
forks from Mre11 resection suggests that BRCA1 may prevent, or compete with, Mre11 
from accessing stalled forks via its supportive role. BRCA1 is known, with 53BP1, to be 
important for the choice between NHEJ and HR, and BRCA1 regulates HR resection by 
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CtIP and Mre11. BRCA2 and Rad51 are also reported to protect stalled forks from Mre11 
resection (Schlacher et al, Cell 2011; Hashimoto Y., Chaudhuri AR. et al, NSMB 2010). 
BRCA1 may function to regulate Mre11 and, potentially, be influential in the choice of 
repair method at stalled forks (Schlacher et al, Cancer Cell 2012). But our results suggest 
BRCA1 does not increase replication fork restart before DSBs are induced.  
The data I have shown are from single experiments and using the HCC1937 cell line, or 
U2OS cell line. Further repeats of these experiments are needed, in both HCC1937 and 
U2OS cells lines and in other non-cancerous breast and cancerous cell lines. It would also 
be interesting to see if similar results were obtained in ovarian cancer cell lines from a 
patient with an inherited BRCA1 mutation. It could also be investigated if the results would 
alter with other mutations in BRCA1, other than the truncated (5382insC) mutant in 
HCC1937, to see which motif in BRCA1 is important for the described phenotype.  
53BP1 data could also be supported by performing pulse-field gel electrophoresis with 
identical samples, confirming the presence and timing of DSBs.  
Further experiments could look at the timing of BRCA1 in the protection of slowed or 
stalled forks, with reference to known stalled fork proteins, such as BRCA2, PARP1, 
Mre11 and Rad51. The order in which they are recruited may give an indication as to the 
molecular reason BRCA1 protects stalled forks from Mre11 resection, how DSBs are 
prevented and how replication restart or DNA repair is organised. 
The accumulation of damage and high level of DNA damage signals in a BRCA1-deficient 
cell line is reflective of BRCA1’s multiple important cellular functions. It is because of its 
importance that when mutations in BRCA1 are inherited the risk of developing breast and 
ovarian cancer is greatly increased. It is important to research the functions and functional 
102 | P a g e  
 
regions of BRCA1 to try to understand it how it causes transformation and to predict the 
effectiveness of cancer therapies. These results suggest the concentration of Gemcitabine at 
the tumour would be important to the resistance of normal and cancer cells and this would 
need further research to define an optimum concentration. The increased levels of 
accumulated damage and less resistance of BRCA1-defective cells to lower concentrations 
of Gemcitabine treatment, suggests that Gemcitabine may be an effective treatment for 
BRCA1 negative cancers. 
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SUPPLEMENTARY FIGURES 
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